



OPEN

Spatial and temporal fluctuations in COVID-19 fatality rates in Brazilian hospitals

Andrea Brizzi^{1,23}, Charles Whittaker^{2,23}, Luciana M. S. Servo^{3,23}, Iwona Hawryluk^{2,23}, Carlos A. Prete Jr^{4,23}, William M. de Souza^{5,23}, Renato S. Aguiar^{6,7}, Leonardo J. T. Araujo⁸, Leonardo S. Bastos⁹, Alexandra Blenkinsop¹, Lewis F. Buss^{2,10}, Darlan Candido¹¹, Marcia C. Castro¹², Silvia F. Costa¹⁰, Julio Croda¹³, Andreza Aruska de Souza Santos¹⁴, Christopher Dye¹¹, Seth Flaxman¹⁵, Paula L. C. Fonseca⁶, Victor E. V. Geddes⁶, Bernardo Gutierrez¹¹, Philippe Lemey¹⁶, Anna S. Levin¹⁰, Thomas Mellan², Diego M. Bonfim⁶, Xenia Miscouridou¹, Swapnil Mishra^{2,17}, Mélodie Monod¹, Filipe R. R. Moreira¹⁸, Bruce Nelson¹⁹, Rafael H. M. Pereira³, Otavio Ranzani²⁰, Ricardo P. Schnekenberg²¹, Elizaveta Semenova¹, Raphael Sonnabend², Renan P. Souza⁶, Xiaoyue Xi¹, Ester C. Sabino¹⁰✉, Nuno R. Faria^{2,10,11,22}✉, Samir Bhatt^{2,17}✉ and Oliver Ratmann^{1,23}✉

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Gamma variant of concern has spread rapidly across Brazil since late 2020, causing substantial infection and death waves. Here we used individual-level patient records after hospitalization with suspected or confirmed coronavirus disease 2019 (COVID-19) between 20 January 2020 and 26 July 2021 to document temporary, sweeping shocks in hospital fatality rates that followed the spread of Gamma across 14 state capitals, during which typically more than half of hospitalized patients aged 70 years and older died. We show that such extensive shocks in COVID-19 in-hospital fatality rates also existed before the detection of Gamma. Using a Bayesian fatality rate model, we found that the geographic and temporal fluctuations in Brazil's COVID-19 in-hospital fatality rates were primarily associated with geographic inequities and shortages in healthcare capacity. We estimate that approximately half of the COVID-19 deaths in hospitals in the 14 cities could have been avoided without pre-pandemic geographic inequities and without pandemic healthcare pressure. Our results suggest that investments in healthcare resources, healthcare optimization and pandemic preparedness are critical to minimize population-wide mortality and morbidity caused by highly transmissible and deadly pathogens such as SARS-CoV-2, especially in low- and middle-income countries.

Since late 2020, emerging variants of concern of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have led to substantial epidemic waves and marked increases in coronavirus disease 2019 (COVID-19) deaths^{1–5}. In Brazil, the SARS-CoV-2 Gamma variant of concern (also known as P.1, 20J/501Y.V3 or GR/501Y.V3, VOC-21JAN-02 or VOC202101/02) was first detected in December 2020 in Manaus, Amazonas state,

in north Brazil^{3,6,7}. Gamma is characterized by several amino acid substitutions in the spike protein, including L18F, N501Y, E484K and K417N, that have been associated with increased transmissibility and immune escape^{3,8,9}. Three weeks after its detection, Gamma became the dominant lineage circulating in Manaus as measured by variant frequency³. The rapid spread of Gamma through the country was followed by waves of COVID-19-associated mortality,

¹Department of Mathematics, Imperial College London, London, UK. ²MRC Centre for Global Infectious Disease Analysis, Jameel Institute, School of Public Health, Imperial College London, London, UK. ³Institute for Applied Economic Research, IPEA, Brasília, Brazil. ⁴Departamento de Engenharia de Sistemas Eletrônicos, Escola Politécnica, Universidade de São Paulo, São Paulo, Brazil. ⁵World Reference Center for Emerging Viruses and Arboviruses and Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston TX, USA. ⁶Departamento de Genética, Ecologia e Evolução, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil. ⁷Instituto D'Or de Pesquisa e Ensino (IDOR), Rio de Janeiro, Brazil. ⁸Laboratory of Quantitative Pathology, Center of Pathology, Adolfo Lutz Institute, São Paulo, Brazil. ⁹Programa de Computação Científica, Fundação Oswaldo Cruz, Rio de Janeiro, Brazil. ¹⁰Departamento de Moléstias Infecciosas e Parasitárias e Instituto de Medicina Tropical da Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil. ¹¹Department of Zoology, University of Oxford, Oxford, UK. ¹²Department of Global Health and Population, Harvard T. H. Chan School of Public Health, Boston MA, USA. ¹³Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven CT, USA. ¹⁴Latin American Centre, University of Oxford, Oxford, UK. ¹⁵Department of Computer Science, University of Oxford, Oxford, UK. ¹⁶Department of Microbiology, Immunology and Transplantation, Rega Institute, KU Leuven – University of Leuven, Leuven, Belgium. ¹⁷Section of Epidemiology, School of Public Health, University of Copenhagen, Copenhagen, Denmark. ¹⁸Departamento de Genética, Instituto de Biologia, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil. ¹⁹Environmental Dynamics, INPA, National Institute for Amazon Research, Manaus, Brazil. ²⁰Barcelona Institute for Global Health, ISGlobal, Barcelona, Spain. ²¹Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK. ²²Department of Infectious Disease Epidemiology, Imperial College London, London, UK. ²³These authors contributed equally: Andrea Brizzi, Charles Whittaker, Luciana M. S. Servo, Iwona Hawryluk, Carlos A. Prete Jr, William M. de Souza, Oliver Ratmann. ✉e-mail: sabinoec@usp.br; n.faria@imperial.ac.uk; s.bhatt@imperial.ac.uk; oratmann@gmail.com




Fig. 1 | Analysis flow chart. Individual-level records of hospital admissions with severe acute respiratory infection across Brazil are mandatory to report to the SIVEP-Gripe database, and publicly available records between 20 January 2020 and 26 July 2021 were downloaded on 31 January 2022. Data used to derive COVID-19 in-hospital fatality rates are shown in blue, and data used to derive the healthcare pressure indices are shown in yellow (Methods).

suggesting increased disease severity after infection and hospitalization with Gamma¹⁰. However, these data have not been examined in the context of extensive inequities in baseline development and healthcare capacity across Brazil, which are common in low- and middle-income countries¹¹.

In this study, we used individual-level patient histories after hospitalization with suspected or confirmed COVID-19 (Fig. 1)^{12,13} to describe how the expansion of Gamma was followed by shocks in COVID-19 fatality rates in Brazilian hospitals, and we showed that in-hospital fatality rates also fluctuated extensively before the emergence of Gamma. We introduced pandemic healthcare pressure indices that measure and monitor mismatches between healthcare demand and resource availability in hospital settings. We found that these pandemic healthcare pressure indices are strongly correlated with variations in in-hospital COVID-19 fatality rates across 14 Brazilian state capitals. Using a Bayesian model, we then assessed the factors driving the extensive fluctuations in COVID-19 in-hospital fatality rates, from pre-pandemic geographic inequities in economic development, healthcare resources and population vulnerability^{14–18}, to pandemic healthcare pressures^{15,19,20} and variant-specific disease

severity as measured by in-hospital fatality rates^{21,22}. Table 1 summarizes our findings and policy implications.

Results

In-hospital fatality rates fluctuated around the emergence of Gamma. With the aim of characterizing longitudinal trends in COVID-19-attributable fatality rates since the beginning of the pandemic, we investigated mortality in hospitalized patients admitted with polymerase chain reaction (PCR)-confirmed, clinically diagnosed or suspected SARS-CoV-2 infection (SARS-CoV-2-attributable infection)¹⁶ from 20 January 2020 to 26 July 2021 across Brazil. We focused on hospital settings, as these are the places where most lives are saved, and we restricted analyses to 14 of 27 Brazilian state capitals for which SARS-CoV-2 genomic data were publicly available from GISAID²³ to characterize the expansion dynamics of Gamma and control for potentially elevated disease severity of Gamma in hospitals (Fig. 2a and Extended Data Fig. 1). In total, 641,618 patients with SARS-CoV-2-attributable infection were admitted to hospitals across the 14 cities and reported to Brazil's Sistema de Informação da Vigilância Epidemiológica da Gripe (SIVEP-Gripe) database (Fig. 1 and Supplementary Table 1). To match these data to city-level transmission dynamics, we retained for analysis the 495,100 COVID-19-attributable hospital admissions among residents in each state capital. We further excluded 32,734 resident patients who were administered at least one vaccine dose before hospitalization to avoid confounding of time trends in fatality rates with vaccine rollout, which occurred during the same period. Thus, our study population comprised the remaining 462,366 COVID-19-attributable hospital admissions in residents (Supplementary Fig. 1). Among those, 120,288 (26.02%) outcomes were fatal. However, 32,585 (7%) admissions had unreported clinical outcomes, which occurred primarily after the detection of Gamma, and so it is important to account for potential underreporting of COVID-19-attributable deaths^{16,24,25}. We estimated 10,029 additional fatalities by considering the proportion of deaths among patients with known outcomes, stratified by age and observation week (Methods, Extended Data Fig. 2 and Supplementary Table 2).

Figure 2c shows the empirical COVID-19 in-hospital fatality rates for Manaus, defined as the proportion of underreporting-adjusted deaths in weekly COVID-19-attributable hospital admissions among residents with no evidence of vaccination before admission (see Extended Data Fig. 3 for four other state capitals). The observed, age-dependent patterns in COVID-19 in-hospital fatality rates are consistent with earlier observations that COVID-19 fatality rates increase with age²⁶. Moreover, we observe, across all age bands, marked increases in COVID-19 in-hospital fatality rates after detection of Gamma, a pattern that is consistent across the 14 cities. However, the within-age band variation reveals stark geographical differences and temporal fluctuations since the beginning of the pandemic rather than just since the emergence of Gamma, reinforcing previous findings on geographical heterogeneity of mortality in the first 3 months of the pandemic¹⁷. For example, in Belo Horizonte, no age group experienced shocks of COVID-19 in-hospital fatality rates above 50% that lasted at least four consecutive weeks, whereas, in Macapá, all age groups of 40 or older experienced such fatality shocks (Supplementary Table 3). We also found that the increases in COVID-19 in-hospital fatality rates after detection of Gamma were largely transient, declining in tandem with fewer admissions, as shown in Fig. 2c for Manaus.

To obtain a simple measure on the extent of spatio-temporal variation, we first estimated smoothed, non-parametric trends through the weekly, age-specific in-hospital fatality rates (Methods). Then, and because the population age compositions vary across cities, we weighted each age-specific trend in a location by the proportion of the 14 cities' populations in the corresponding age band, resulting in

Table 1 | Policy summary

Background	Little research has put the evolving COVID-19 pandemic into the wider focus of healthcare inequities and pandemic healthcare pressure in low- and middle-income countries.
Main findings and limitations	For Brazil, we show that COVID-19 fatality rates in hospitals have fluctuated substantially both geographically and temporally since the beginning of the pandemic. In several cities, shock periods are characterized by in-hospital fatality rates exceeding 50% in patients aged 70 years and older. Using healthcare-facility-level microdata on personnel and equipment, we measured healthcare pressure at the city level and found strong associations with the fluctuating COVID-19 in-hospital fatality rates. These associations are confirmed in a Bayesian model that accounts for the emergence and rapid spread of the SARS-CoV-2 Gamma variant. We estimate that approximately half of Brazil's COVID-19 deaths in hospitals could have been avoided without pre-pandemic geographic inequities and without the multitude of pandemic healthcare pressures. Limitations of this study include sparsely available data on patient comorbidity factors and incomplete data on patient outcomes.
Policy implications	Our findings show that COVID-19 fatality rate shocks seen in Brazilian hospitals can be explained by a substantially increased demand on limited healthcare resources that follow SARS-CoV-2 infection waves. The conclusions are relevant for other countries and show that responding to acute healthcare shocks is challenging. Without sustained investments in healthcare resources, healthcare optimization and pandemic preparedness to minimize population-wide mortality and morbidity, countries will continue to experience high fatality rates caused by immune-escape SARS-CoV-2 variants and other highly transmissible viruses.

age-standardized estimates of weekly COVID-19 in-hospital fatality rates. Figure 3a shows the age-standardized COVID-19 in-hospital fatality rates since the beginning of the pandemic across locations in black lines, and Table 2 reports the minimum and maximum observed values in each location. The minimum age-standardized in-hospital fatality rates occurred either at the start of the observation period or between waves of hospital admissions in each location for all cities except Belo Horizonte, where the lowest fatality rates were seen at the end of the observation period. We performed additional analyses suggesting that this further drop in fatality rates in Belo Horizonte at the end of the observation period is likely related to missing data on vaccine status in hospitalized patients in Belo Horizonte (Supplementary Fig. 2). For this reason, and to guard our analyses against other potential confounders, such as improved treatment with dexamethasone, we evaluated the minimum fatality rates over the period until the detection of Gamma. In Belo Horizonte, the minimum age-standardized COVID-19 in-hospital fatality rate before detection of Gamma was 7.7%, and the maximum value over the entire study period was 12.7%, a 1.64-fold increase. We observed higher fold increases in all other state capitals, apart from Rio de Janeiro where age-standardized in-hospital fatality rates were very high throughout the study period. Rates tended to reach similar baseline values between shock periods in each location and were lowest in state capitals from the South and Southeast regions of Brazil. The maximum rates occurred in most locations

after the first detection of Gamma, except for João Pessoa, Macapá and Rio de Janeiro where they occurred before the first detection of Gamma. Overall, rates tended to be highest in the North, Northeast and Center-West regions of Brazil.

Healthcare pressure indices track in-hospital fatality rates. Since the early phase of the COVID-19 pandemic, investments to avoid a widespread collapse of Brazil's unified health system have resulted in increased availability of equipment such as ventilators and intensive care unit (ICU) beds as well as trained healthcare professionals—but with considerable geographic differences^{19,27}. In the wider context of substantial underfunding of Brazil's unified health system before the pandemic^{14,28} and disparities in healthcare resources across and within Brazil's states²⁹, here we introduce pandemic healthcare pressure indices that monitor in-hospital healthcare load at the city level. We obtained healthcare-facility-level microdata on personnel (nurses, nurse assistants, physiotherapists, physicians and intensive care specialists) and equipment (critical care beds, ICU beds and ventilators) from Brazil's National Register of Health Facilities (Cadastro Nacional de Estabelecimentos de Saúde (CNES)), which we consolidated into monthly time series for each location (Methods).

We found large inequities in healthcare resources across Brazil. In March 2020 the number of available ventilators per 100,000 population ranged from 21.7 in Macapá to 102 in Porto Alegre, and the number of physicians per 100,000 population ranged from 124 in Macapá to 631 in Belo Horizonte (Supplementary Table 4). From these data, we constructed healthcare pressure indices that capture changes in hospital demand per available resource, with demand comprising all hospitalized patients with severe acute respiratory infection, including non-residents and individuals with vaccine breakthrough infections (Fig. 1 and Methods). One such index, the moving sum of ICU admissions over 3 weeks per ICU bed, is shown in Fig. 3a, and four further indices are shown in Extended Data Figs. 4 and 5. We found that all healthcare pressure indices are strongly correlated with the age-standardized, weekly COVID-19 in-hospital fatality rates in most cities, except Florianópolis (Fig. 3b).

The effects of severity, location and pandemic healthcare pressure.

We next developed a Bayesian multi-strain fatality model to disentangle the effects of location-specific inequities, pandemic healthcare pressures and Gamma-specific disease severity on fluctuating COVID-19 in-hospital fatality rates while accounting for the substantial cumulated loss of life³⁰ and age-prioritized vaccine rollout^{10,21,22}. In brief, the model reconstructs the replacement dynamics of Gamma in each of the 14 state capitals from weekly SARS-CoV-2 sequence metadata and estimates the weekly number of patients who are hospitalized, respectively, with Gamma and non-Gamma SARS-CoV-2 infection in 11 age strata. We modeled age-specific in-hospital fatality rates for each variant through a regression equation that captures non-parametric location effects, fixed non-negative effects associated with the healthcare pressure indices and non-parametric virus variant effects associated with the replacement dynamics of Gamma (Methods). In the model, the non-parametric location effects do not vary in time and account for a variety of constant social, economic or healthcare-related factors that differentiate one city from another in the weeks when their observed fatality rates were lowest, such as the prevalence of comorbidities that might modify disease severity or pre-existing inequities in both the quality and the quantity of available healthcare resources^{15,31}. By contrast, the healthcare pressure indices vary in time, and the strength of their association with the fatality rates is estimated through the regression equation. Patients estimated to have been infected with the Gamma variant are in the model considered separately from those estimated to have been infected with non-Gamma variants of SARS-CoV-2, which allowed us to control for Gamma-specific expansion and in-hospital disease severity when inferring associations between fatality rates and healthcare pressure.




Fig. 2 | Spatio-temporal expansion of SARS-CoV-2 Gamma in Brazil and associated shocks in COVID-19 fatality rates in hospitals. a, The 14 states and state capitals in which Gamma was detected by 31 March 2021 and which were included in the analysis. **b,** Time evolution of SARS-CoV-2 Gamma variant frequencies in three locations, suggesting rapid expansion. Data from GISAID²³ (dots) are shown along with the number of sequenced SARS-CoV-2 samples (text) and posterior median model fits (line) and associated 95% CIs (gray ribbon). **c,** Weekly COVID-19 in-hospital fatality rates among hospitalized residents in Manaus with no evidence of vaccination before admission (dots), by age group (facets). Non-parametric loess mean estimates of time trends are shown as block solid lines along with 95% confidence intervals as gray ribbons. The date of Gamma's first detection is indicated as the gray dotted vertical line.

Brazil's rapid vaccination rollout overlapped with the temporal expansion of Gamma as well as changes in Brazil's age-specific population structure³⁰. To account for this, we used all-cause death records from Brazil's Civil Registry and vaccine administration records from the Brazilian Ministry of Health to adjust downwards the population at risk of hospitalization per location and age group in the model (Methods). We observed substantial variation in the timing of vaccine rollout, time to second dose and vaccine type administered (Supplementary Figs. 3–7). Accounting for this variation was important to obtain good model fit to age-specific

shifts in hospital admissions, deaths in hospitalized patients, in-hospital fatality rates and variant frequencies of Gamma (Extended Data Figs. 1 and 6–9).

Regional and healthcare inequities drive in-hospital fatality rates. Figure 4a compares the fitted age-standardized COVID-19 in-hospital fatality rates across Brazil's macroregions—the North, Northeast, Central-West, Southeast and South—revealing considerable geographical heterogeneity. Before the first detection of Gamma in each location, the fitted age-standardized in-hospital fatality rate




Fig. 3 | Time trends in age-standardized COVID-19 in-hospital fatality rates and pandemic healthcare pressure. a, Non-parametric median estimates (lines) and 95% confidence interval (ribbons) of age-standardized COVID-19 in-hospital fatality rates (black, right-hand-side axis) are shown against the healthcare pressure index of ICU admissions over 3 weeks per available ICU bed in each city (color, left-hand-side axis). The date of first detection of Gamma is added as a vertical dashed line. **b**, Heat map of Pearson correlation coefficients between age-standardized in-hospital fatality rates and each pandemic healthcare pressure index. SARI, severe acute respiratory infection; wk, week.

Table 2 | Temporal fluctuations in COVID-19-attributable in-hospital fatality rate and avoidable COVID-19-attributable deaths in hospitals

Location	Observation period	COVID-19 attributable hospital admissions in unvaccinated residents		Age-standardized weekly COVID-19 in-hospital fatality rate (HFR)			Estimated avoidable COVID-19 deaths in hospitals	
		Total	Deaths ^a	Lowest (%) ^b	Highest (%) ^b	Fold increase ^b	Assuming the lowest HFR in each city (%) ^c	Assuming the lowest HFR across all 14 cities (%) ^c
Belo Horizonte	06/04/20–26/07/21	42,113	7,692	7.7	12.7	1.64	29.1 (24.6–33.7)	29.1 (24.6–33.7)
Curitiba	02/03/20–26/07/21	33,015	7,535	8.1	18.1	2.23	39.6 (34.2–44.7)	47.3 (43.9–50.8)
Florianópolis	09/03/20–26/07/21	4,032	893	7.8	17.1	2.20	22.9 (12.5–32.6)	44.5 (40.9–48.1)
Goiânia	16/03/20–26/07/21	20,044	6,246	11.6	25.9	2.23	44.7 (39.0–50.0)	61.2 (58.6–63.7)
João Pessoa	09/03/20–26/07/21	10,552	3,636	15.3	29.7	1.94	18.8 (13.0–25.1)	65.9 (63.7–68.1)
Macapá	30/03/20–26/07/21	3,169	1,011	11.0	41.5	3.78	41.6 (30.5–51.8)	68.4 (66.2–70.6)
Manaus	24/02/20–26/07/21	26,260	10,168	16.4	33.4	2.04	39.3 (35.9–42.3)	70.9 (69–72.9)
Natal	16/03/20–26/07/21	9,344	3,512	11.4	32.9	2.87	35.4 (30.2–40.5)	66.9 (64.8–69)
Porto Alegre	02/03/20–26/07/21	16,106	5,266	8.6	27.1	3.16	41.8 (37.7–45.7)	59.6 (57.1–62.3)
Porto Velho	30/03/20–26/07/21	6,795	2,473	11.5	32.2	2.79	39.1 (32.2–45.5)	70.3 (68.3–72.4)
Rio de Janeiro	16/03/20–26/07/21	73,139	28,053	19.2	26.0	1.35	10.2 (8.5–11.9)	66.9 (64.8–69)
Salvador	16/03/20–26/07/21	26,964	8,509	9.7	26.9	2.76	20.8 (16.2–25.2)	61.3 (58.8–63.9)
São Luís	24/02/20–26/07/21	8,545	2,547	8.2	26.5	3.25	35.7 (28.4–42.4)	60.5 (57.9–63.1)
São Paulo	20/01/20–26/07/21	182,288	42,769	8.8	19.8	2.24	36.2 (33.9%–38.4)	50.1 (46.9–53.4)
All 14 cities	20/01/20–26/07/21	462,366	130,317				29.8 (28.7–30.9)	57.1 (54.3–59.9)

^aObserved deaths plus expected deaths in COVID-19-attributable hospital admissions with unreported outcome. ^bAge-specific COVID-19-attributable in-hospital fatality rates were estimated from linked data on underreporting-adjusted deaths in COVID-19-attributable hospital admissions. Non-parametric loess estimates were obtained and weighted by the population age composition across cities. Lowest fatality rates were calculated in the period before Gamma's first detection in each location, and highest fatality rates were calculated including the time after Gamma's first detection. The lowest fatality rates in the period before Gamma's first detection agreed with those observed across the entire study period for all cities except Belo Horizonte. See the main text for further details and analyses. ^cEstimates are based on hypothetical scenarios evaluated under the Bayesian multi-strain fatality model, assuming the lowest observed in-hospital fatality rates seen in the periods before Gamma's first detection in each location.

was lowest in Belo Horizonte and highest in Rio de Janeiro (shown as dotted horizontal lines in Fig. 4a). The high estimates for Rio de Janeiro prompted us to compare excess deaths derived from Brazilian's Civil Registry to the COVID-19-attributable in-hospital deaths, which suggested that a smaller than expected proportion of hospitalized patients with unreported clinical outcomes may have died. However, Rio de Janeiro's age-standardized COVID-19 fatality rates remained the highest even when we assume that all patients with unreported clinical outcomes were successfully treated and survived COVID-19 (Methods and Supplementary Fig. 8).

Figure 4b–d compares the estimated location and the Gamma and healthcare pressure contributions to in-hospital fatality rates (Methods). We found that the marked increase in COVID-19 in-hospital fatality rates is better explained by changes in healthcare pressures rather than a direct effect of Gamma on fatality rates in hospitalized patients. This result is inferred from three observations. First, the empirical in-hospital fatality rates also fluctuated before the detection of Gamma; second, the rates largely decreased after the initial shock after Gamma detection; and third, the rates were strongly associated with the time-varying pandemic healthcare pressure indices (Extended Data Fig. 8). Relative to Belo Horizonte, the lowest fatality rates were an estimated 1.95-fold (95% credible interval (CrI): 1.11–3.25) higher in all other state capitals, a location effect that was consistent across all age groups. Although we do not explore the exact drivers of this location effect, it is likely shaped by a combination of socioeconomic factors specific to each city, in conjunction with city-specific, pre-existing inequities in the availability, quality and accessibility of healthcare^{32,33}. At peak times, pandemic healthcare pressures as measured by our indices were associated with a 2.33-fold (95% CrI: 1.39–4.27) multiplicative effect across the 14 cities, and this contribution was stronger in places that already

had high in-hospital fatality rates at baseline. Gamma was not associated with a statistically significant effect on in-hospital fatality rates after controlling for healthcare pressures (posterior $P=0.14$ that Gamma-specific in-hospital disease severity is lower than or equal to that of non-Gamma variants in patients aged 30–39 years compared to non-Gamma variants of SARS-CoV-2 and larger in those younger than 30 years and older than 39 years).

Avoidable deaths in the absence of resource limitations. To quantify the effect that the observed fluctuations in COVID-19-attributable in-hospital rates had on the death toll in the 14 state capitals, we considered counterfactual simulations where infection waves and resource limitations did not result in surging in-hospital fatality rates (Methods). We consider this counterfactual scenario conservative as it assumes, for each location, achievable in-hospital fatality rates that are based on the lowest values observed before the first detection of Gamma in each state capital and, thus, before subsequent improvements in clinical management, patient triage and treatments (for example, dexamethasone). Across the 14 state capitals, we found that, in the absence of pandemic resource limitations, deaths could have been reduced by an estimated 29.8% (95% CrI: 28.7–30.9%) (Table 2).

Using additional counterfactual simulations, we further evaluated how many in-hospital deaths could have been avoided in the absence of regional inequities and pandemic resource limitations—that is, if all 14 state capitals would have experienced throughout the pandemic the lowest observed in-hospital fatality rates across all 14 cities, which were found in Belo Horizonte. We consider these estimations less conservative, because the observed, low in-hospital fatality rates in Belo Horizonte could reflect a large range of factors that might not be translatable to other locations in Brazil. We found

that in-hospital deaths could have been reduced by an estimated 57.1% (95% CrI: 54.3–59.9%) in the 14 state capitals (Table 2).

Discussion

This study highlights extensive geographic and temporal variation in COVID-19 in-hospital fatality rates since the beginning of the epidemic in 14 state capitals across Brazil. Our analyses indicate that the observed variation is driven primarily by shortages in healthcare capacity, which, in turn, emerged from a combination of pre-pandemic regional inequities and increased healthcare pressure brought about by epidemic waves of SARS-CoV-2 transmission. The extent and degree of this mismatch between supply (of staff and equipment) and demand (patients requiring hospitalization for COVID-19) is highly dynamic, varying considerably over the course of the epidemic with the magnitude of each infection wave.

Our findings should be considered in the context of the following limitations. First, Brazil's inpatient records are limited in that comorbidity factors, vaccination status or SARS-CoV-2 variant information are either frequently missing or not available at the individual level³⁴. This makes it challenging to comprehensively control for individual-level factors that can modulate fatality rates^{35,36}. However, Brazil's freely accessible inpatient data constitute one of the world's largest databases to characterize the pandemic effect of COVID-19 in a middle-income country and across areas that differ substantially in baseline development and available healthcare resources. In sensitivity analyses, we considered SARS-CoV-2 sequence data from alternative sources as well as alternative patient inclusion criteria, which suggest that our estimates of location and healthcare pressure effect sizes are robust (Supplementary Figs. 9–14).

Second, here we delineate fluctuations in COVID-19 in-hospital fatality rates at city level to focus on the extensive spatio-temporal heterogeneity in fatality rates across Brazil. We recognize that this broader geographic focus masks important differences within cities, and, thus, we cannot identify the exact factors determining the substantial location effects that we measure. However, these are likely related to (1) differences in catchment populations, as vulnerable populations with poor healthcare access are highly clustered across Brazil's largest cities^{29,37}; (2) underfunding of the public healthcare system^{14,28} and emerging discrepancies in healthcare resources compared to private hospitals^{17,32,37,38}; or (3) inequities in the quality and capabilities of healthcare systems that are well-documented—for example, for pre-pandemic sepsis survival rates³⁹. Additional relevant factors could include (4) differences in demand reflecting variation in epidemic magnitude³² and (5) the timing and extent of public health measures aimed at controlling spread and preventing infection in vulnerable groups^{19,27,33}. As such, the location effects could also reflect healthcare pressures that are present already at the lowest incidences of COVID-19 hospital admissions in each location. We observed substantial fluctuations in in-hospital fatality rates even in private hospitals of São Paulo city (Supplementary Fig. 15), suggesting that large effects of healthcare pressure on in-hospital fatality rates are common across Brazil.

Third, the pandemic healthcare pressure indices that we derived are based on data reported to CNES, which does not capture all resource limitations, such as the acute shortages in oxygen supply that were experienced in January 2021 in Manaus⁴⁰, and is prone to potential reporting biases²⁰. In our view, the inferred associations between healthcare pressure indices and fatality rates demonstrate that, where resources are limited, real-time monitoring of available resources is especially important to identify critical resource limitations and avoid the lamentable shocks in death rates that we describe for many state capitals across Brazil.

Fourth, in characterizing hospital fatality rates in a broad Brazilian context, we are ignoring historical policy aspects that can be a source of heterogeneity. The standard of healthcare per unit staff member can be improved by federal coordinated actions and

policies on training as well as unambiguous governmental medical policies to prevent disinformation⁴¹. These federal policies also extend to financing to ensure that the underlying structure of primary care and emergency services all present a standardized quality of care⁴².

Finally, our analyses start with hospitalization, which is a limitation because in-hospital fatality rates also depend on which, and under what circumstances, severely ill patients are admitted to hospitals. Thus, it is possible that healthcare demand was amplified due to an increased risk of hospitalization after infection with a variant of concern with higher infection severity, as has been shown for SARS-CoV-2 Alpha^{35,43}. We also found evidence that, in several locations, out-of-hospital deaths surged at times of peak demand (Extended Data Fig. 2), and that, in hospitalized patients with a fatal outcome, the time to death after admission tended to be shorter during peak demand (Supplementary Fig. 16). These observations indicate that increased healthcare pressure acts to shape in-hospital fatality rates through distinct mechanisms, likely through a combination of both the reduced ability to provide adequate care and an increase in the average severity of admitted patients (with only the most severely ill admitted during periods of highest pressure). In this context, if less severe COVID-19 cases could also have been admitted, we expect that the estimated proportion of avoidable COVID-19 in-hospital deaths in the absence of healthcare pressure effects would be lower than what is reported here. At the same time, the projected numbers are likely an underestimate of COVID-19 deaths that could have been avoided in the absence of healthcare pressure effects because we did not account for deaths in severely ill individuals who were not cared for in hospitals.

It can be challenging to generalize the effects of healthcare pressure indices to other countries and in different temporal waves of the pandemic. The concept of health system resilience is well-studied^{44–46}. However, our results highlight that established indices such as the Global Health Security Index⁴⁷ are inadequate to reliably measure healthcare resilience. Similar results to what we have presented in this study have been found in Greece, Israel and the United States^{48–50}. The factors affecting in-hospital fatality rates in Brazil are universal and highlight that healthcare resilience cannot be simply solved by responding to short-term shocks or attempting to dynamically redistribute capacity. Instead, it requires an investment in long-term measures, such as training healthcare workers, strengthening public health functions and funding in excess of current need⁵¹.

The implications of the inferred scale of location inequities and healthcare shortages in Brazil are substantial. As of 26 July 2021, we estimate that approximately one-quarter of the COVID-19-attributable deaths in the hospitals in the 14 cities studied could have been avoided if healthcare pressure had not exacerbated baseline fatality rates. Taking the percent reduction across the 14 state capitals as indicative and generalizable to all of Brazil, we estimate that, as of 26 July 2021, 176,399 (169,888–182,911) of Brazil's observed 591,945 COVID-19-attributable deaths in hospitals could have been avoided in the absence of pandemic resource limitations. We also estimate that approximately half of the COVID-19-attributable deaths in the hospitals in the 14 cities studied could have been avoided if, in addition, all hospitals would have had the same baseline COVID-19 fatality rates as those observed in Belo Horizonte. Extrapolating Belo Horizonte's lowest observed in-hospital fatality rates to all of Brazil, we estimate that, as of 26 July 2021, 337,763 (321,485–354,575) of Brazil's COVID-19-attributable in-hospital deaths could have been avoided. Our findings are particularly important in calibrating the risk posed by new SARS-CoV-2 variants of concern. We find that the effect of Gamma in Brazil's hospitals has predominantly been indirect and mediated through pre-existing geographic inequities, transient infection waves and concomitant shocks in healthcare demand. In conclusion, our




Fig. 4 | Estimated contribution of location effects, infection severity of Gamma and pandemic healthcare pressure on COVID-19 in-hospital fatality rates.

a, Estimated weekly age-standardized COVID-19 in-hospital fatality rates, averaged across SARS-CoV-2 variants. Posterior median estimates (line) are shown with 95% CrIs (ribbon) and the lowest estimated fatality rates before detection of Gamma in each state capital (dotted horizontal line). **b**, Estimated ratio in lowest in-hospital fatality rates in each location relative to that seen in Belo Horizonte. **c**, Estimated ratio in in-hospital fatality rates for Gamma versus non-Gamma lineages of SARS-CoV-2. **d**, Estimated multiplier to the lowest age-standardized fatality rates before Gamma's detection shown in **a**, which is associated with the pandemic healthcare pressure indices. In each plot, posterior median estimates are shown as dots and 95% CrIs as linerange. Box plots summarize posterior medians across locations ($n = 14$): the middle line is the median; the box limits represent the upper and lower quartiles; and the whiskers extend to the extreme values that are no further than 1.5 times the interquartile range. Multipliers and ratios in **b-d** are reported on a logarithmic scale. Posterior estimates with CrI width larger than 3 were removed for clarity of presentation.

results suggest that investments in healthcare resources, healthcare optimization and pandemic preparedness are critical to minimize population-wide mortality and morbidity caused by highly transmissible and deadly pathogens such as SARS-CoV-2, especially in low- and middle-income countries.

Online content

Any methods, additional references, Nature Research reporting summaries, source data, extended data, supplementary information, acknowledgements, peer review information; details of author contributions and competing interests; and statements of data and code availability are available at <https://doi.org/10.1038/s41591-022-01807-1>.

Received: 4 November 2021; Accepted: 31 March 2022;

Published online: 10 May 2022

References

- Davies, N. G. et al. Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England. *Science* **372**, eabg3055 (2021).
- Tegally, H. et al. Detection of a SARS-CoV-2 variant of concern in South Africa. *Nature* **592**, 438–443 (2021).
- Faria, N. R. et al. Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus, Brazil. *Science* **372**, 815–821 (2021).
- Volz, E. et al. Assessing transmissibility of SARS-CoV-2 lineage B.1.1.7 in England. *Nature* **593**, 266–269 (2021).
- Dyer, O. Covid-19: South Africa's surge in cases deepens alarm over omicron variant. *BMJ* **375**, n3013 (2021).
- Naveca, F. G. et al. COVID-19 in Amazonas, Brazil, was driven by the persistence of endemic lineages and P.1 emergence. *Nat. Med.* **27**, 1230–1238 (2021).
- Fujino, T. et al. Novel SARS-CoV-2 variant in travelers from Brazil to Japan. *Emerg. Infect. Dis.* **27**, 1243–1245 (2021).
- Harvey, W. T. et al. SARS-CoV-2 variants, spike mutations and immune escape. *Nat. Rev. Microbiol.* **19**, 409–424 (2021).
- Souza, W. M. et al. Neutralisation of SARS-CoV-2 lineage P.1 by antibodies elicited through natural SARS-CoV-2 infection or vaccination with an inactivated SARS-CoV-2 vaccine: an immunological study. *Lancet Microbe* **2**, 527–535 (2021).
- Martins, A. F. et al. Detection of SARS-CoV-2 lineage P.1 in patients from a region with exponentially increasing hospitalisation rate, February 2021 Rio Grande do Sul, Southern Brazil. *Euro Surveill.* **26**, 2100276 (2021).
- Walker, P. G. T. et al. The impact of COVID-19 and strategies for mitigation and suppression in low- and middle-income countries. *Science* **369**, 413–422 (2020).
- SRAG 2020 - Banco de Dados de Síndrome Respiratória Aguda Grave. *openDataSUS* <https://opendatasus.saude.gov.br/dataset/srag-2020> (2020).
- SRAG 2021 e 2022 - Banco de Dados de Síndrome Respiratória Aguda Grave. *openDataSUS* <https://opendatasus.saude.gov.br/dataset/srag-2021-e-2022> (2021).
- Castro, M. C. et al. Brazil's unified health system: the first 30 years and prospects for the future. *Lancet* **394**, 345–356 (2019).
- de Oliveira Andrade, R. COVID-19 is causing the collapse of Brazil's national health service. *BMJ* **370**, m3032 (2020).
- de Souza, W. M. et al. Epidemiological and clinical characteristics of the COVID-19 epidemic in Brazil. *Nat. Hum. Behav.* **4**, 856–865 (2020).
- Ranzani, O. T. et al. Characterisation of the first 250 000 hospital admissions for COVID-19 in Brazil: a retrospective analysis of nationwide data. *Lancet Respir. Med.* **9**, 407–418 (2021).
- Li, S. L. et al. Higher risk of death from COVID-19 in low-income and non-White populations of São Paulo, Brazil. *BMJ Glob. Health* **6**, e004959 (2021).
- Albuquerque, M. V. D. & Ribeiro, L. H. L. Inequality, geographic situation, and meanings of action in the COVID-19 pandemic in Brazil. *Cad. Saude Publica* **36**, e00208720 (2021).
- Rocha, T. A. H. et al. National registry of health facilities: data reliability evidence. *Cien. Saude Colet.* **23**, 229–240 (2018).
- de Oliveira, M. H. S., Lippi, G. & Henry, B. M. Sudden rise in COVID-19 case fatality among young and middle-aged adults in the south of Brazil after identification of the novel B.1.1.28.1 (P.1) SARS-CoV-2 strain: analysis of data from the state of Paraná. Preprint at *medRxiv* <https://doi.org/10.1101/2021.03.24.21254046> (2021).
- Freitas, A. R. R. et al. The emergence of novel SARS-CoV-2 variant P.1 in Amazonas (Brazil) was temporally associated with a change in the age and sex profile of COVID-19 mortality: a population based ecological study. *Lancet Reg. Health Am.* **1**, 100021 (2021).
- Shu, Y. & McCauley, J. GISAID: Global Initiative on Sharing All Influenza Data—from vision to reality. *Euro Surveill.* **22**, 30494 (2017).
- Fellows, M. et al. Under-reporting of COVID-19 cases among indigenous peoples in Brazil: a new expression of old inequalities. *Front. Psychiatry* **12**, 352 (2021).
- Veiga E Silva, L. et al. COVID-19 mortality underreporting in Brazil: analysis of data from government internet portals. *J. Med. Internet Res.* **22**, e21413 (2020).
- Brazeau, N. et al. Report 34: COVID-19 Infection Fatality Ratio: Estimates from Seroprevalence (Imperial College London, 2020); <https://doi.org/10.25561/83545>
- Rocha, R. et al. Effect of socioeconomic inequalities and vulnerabilities on health-system preparedness and response to COVID-19 in Brazil: a comprehensive analysis. *Lancet Glob. Health* **9**, 782–792 (2021).
- Funcia, F. R. Underfunding and federal budget of SUS: preliminary references for additional resource allocation. *Cien. Saude Colet.* **24**, 4405–4415 (2019).
- Pereira, R. H. M. et al. Geographic access to COVID-19 healthcare in Brazil using a balanced float catchment area approach. *Soc. Sci. Med.* **273**, 113773 (2021).
- Castro, M. C. et al. Reduction in life expectancy in Brazil after COVID-19. *Nat. Med.* **27**, 1629–1635 (2021).
- Clark, A. et al. Global, regional, and national estimates of the population at increased risk of severe COVID-19 due to underlying health conditions in 2020: a modelling study. *Lancet Glob. Health* **8**, 1003–1017 (2020).
- Castro, M. C. et al. Spatiotemporal pattern of COVID-19 spread in Brazil. *Science* **372**, 821–826 (2021).
- de Souza Santos, A. A. et al. Dataset on SARS-CoV-2 non-pharmaceutical interventions in Brazilian municipalities. *Sci. Data* **8**, 73 (2021).
- Brito, A. F. et al. Global disparities in SARS-CoV-2 genomic surveillance. Preprint at *medRxiv* <https://doi.org/10.1101/2021.08.21.21262393> (2021).
- Sheikh, A., McMenamin, J., Taylor, B. & Robertson, C. SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness. *Lancet* **397**, 2461–2462 (2021).
- Davies, N. G. et al. Increased mortality in community-tested cases of SARS-CoV-2 lineage B.1.1.7. *Nature* **593**, 270–274 (2021).
- Nicolelis, M. A., Raimundo, R. L., Peixoto, P. S. & Andreazzi, C. S. The impact of super-spreader cities, highways, and intensive care availability in the early stages of the COVID-19 epidemic in Brazil. *Sci. Rep.* **11**, 13001 (2021).
- Noronha, K. V. M. D. S. et al. Pandemia por COVID-19 no Brasil: análise da demanda e da oferta de leitos hospitalares e equipamentos de ventilação assistida segundo diferentes cenários. *Cad. Saude Publica* <https://doi.org/10.1590/0102-311X00115320> (2020).
- Machado, F. R. et al. The epidemiology of sepsis in Brazilian intensive care units (the Sepsis PREvalence Assessment Database, SPREAD): an observational study. *Lancet Infect. Dis.* **17**, 1180–1189 (2017).
- Malta, M., Strathdee, S. A. & Garcia, P. J. The Brazilian tragedy: where patients living at the Earth's lungs die of asphyxia, and the fallacy of herd immunity is killing people. *EclinicalMedicine* **32**, 100757 (2021).
- Leite, S. N. et al. Management of the health workforce in facing COVID-19: disinfection and absences in Brazil's public policies. *Cien. Saude Colet.* **26**, 1873–1884 (2021).
- Mendes, Á., Carnut, L. & Guerra, L. D. D. S. Primary health care federal funding in the Unified Health System: old and new dilemmas. *Saúde em Debate* <https://doi.org/10.1590/0103-11042018S115> (2018).
- Grint, D. J. et al. Severity of SARS-CoV-2 alpha variant (B.1.1.7) in England. *Clin. Infect. Dis.* <https://doi.org/10.1093/cid/ciab754> (2021).
- Haldane, V. et al. Health systems resilience in managing the COVID-19 pandemic: lessons from 28 countries. *Nat. Med.* **27**, 964–980 (2021).
- Hiam, L. & Yates, R. Will the COVID-19 crisis catalyse universal health reforms? *Lancet* **398**, 646–648 (2021).
- Lal, A., Erond, N. A., Heymann, D. L., Gitahi, G. & Yates, R. Fragmented health systems in COVID-19: rectifying the misalignment between global health security and universal health coverage. *Lancet* **397**, 61–67 (2021).
- Baum, F. et al. Explaining covid-19 performance: what factors might predict national responses? *BMJ* **372**, n91 (2021).
- Lytras, T. & Tsiodras, S. Total patient load, regional disparities and in-hospital mortality of intubated COVID-19 patients in Greece, from September 2020 to May 2021. *Scan. J. Public Health* **14034948211059968** (2021).
- Kadri, S. S. et al. Association between caseload surge and COVID-19 survival in 558 US hospitals, March to August 2020. *Ann. Intern. Med.* **74**, 1240–1251 (2021).
- Rossman, H. et al. Hospital load and increased COVID-19 related mortality in Israel. *Nat. Commun.* **12**, 1904 (2021).
- Sirleaf, E. J. & Clark, H. Report of the Independent Panel for Pandemic Preparedness and Response: making COVID-19 the last pandemic. *Lancet* **398**, 101–103 (2021).

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other

third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2022

Methods

To characterize the role of pre-pandemic geographic inequities and increased healthcare pressure brought about by epidemic waves of SARS-CoV-2 transmission, we took a systematic approach that involved longitudinal statistical analyses of hospitalized patients with suspected or confirmed COVID-19 infection in 14 state capitals of 27 Brazilian federal states, longitudinal analyses of healthcare resources in each city, mathematical modelling to disentangle the effect of geographic inequities and healthcare pressure from Gamma's rapid expansion across Brazil and validation against external data. The following sections summarize our methods. All data used are publicly available, and no further ethics consent was required. Code and data are fully available (see 'Data availability' section).

Data to characterize in-hospital fatality rates. We obtained publicly available individual records of patients with severe acute respiratory infection in public or private hospitals across Brazil that were reported in the SIVEP-Gripe database, release 31 January 2022 (<https://opendatasus.saude.gov.br/dataset/srag-2020>, <https://opendatasus.saude.gov.br/dataset/srag-2021-e-2022>).

Individual patient records in Brazil's SIVEP-Gripe database do not contain linked SARS-CoV-2 sequence data. To characterize the associations and effect sizes of geographic inequities and healthcare pressure on COVID-19 in-hospital fatality rates while controlling for variant-specific effects of Gamma on in-hospital severity, we focused analyses on geographically well-defined locations where SARS-CoV-2 sequence metadata were independently and freely available. We searched GISAID (<https://www.gisaid.org>) on 14 June 2021 for sequence data associated with SARS-CoV-2 Gamma virus genome sequences in the 27 federal units (26 Brazilian states and the Federal District). Gamma genome data were available for 16 federal units: Amapá, Amazonas, Bahia, Goiás, Maranhão, Mato Grosso do Sul, Minas Gerais, Paraíba, Paraná, Rio de Janeiro, Rio Grande do Norte, Rio Grande do Sul, Rondônia, Santa Catarina, São Paulo and Tocantins. We focused our analysis on the state capitals in these federal units because key variables, such as population size, vaccination coverage and healthcare indicators, were more directly available at the level of state capitals. We assumed that the frequency of Gamma in state capitals is similar to the frequency of Gamma across that state, measured by available sequence metadata. Two state capitals, Palmas and Campo Grande, were excluded from further analysis due to limited, weekly age-specific COVID-19 hospital admission and death counts of residents reported to the SIVEP-Gripe database. The cities in our sampling frame were, thus, Belo Horizonte, Curitiba, Florianópolis, Goiânia, João Pessoa, Macapá, Manaus, Natal, Porto Alegre, Porto Velho, Rio de Janeiro, Salvador, São Luís and São Paulo. Reflecting the geographical expansion of COVID-19 through Brazil over time, our observation periods varied across cities. The start dates were defined as the Monday after the date on which at least 2.5 patients with suspected or confirmed COVID-19 per 100,000 population were hospitalized in each location. The end date was set to 26 July 2021 (Supplementary Table 1). Records were filtered to exclude out-of-hospital deaths, defined as individuals with a missing hospital admission date or who died on the day of admission; to exclude confirmed infections with other respiratory pathogens or with missing diagnosis; to exclude non-residents to match city-level population denominators; and to exclude patients with at least one vaccine dose before hospital admission to that ensure that trends in fatality rates were not confounded with vaccine status. To avoid bias⁴⁶, our data, thus, included patients with PCR-confirmed, clinically diagnosed or suspected COVID-19 infection (Supplementary Fig. 17). Alternative inclusion criteria were considered in sensitivity analyses and are reported below. The data are available at [inst/data/SIVEP_hospital_31-01-2022-all.rds](https://github.com/inst/data/SIVEP_hospital_31-01-2022-all.rds) in the GitHub repository.

Population size estimates in each city were retrieved by sex and 1-year age bands from the 2020 National Household Sample Survey COVID-19, Pesquisa Nacional por Amostra de Domicílios COVID-19 (ref. ⁵²). The projections were reconciled with available vaccination records of residents in each city, so that, at most, 99% of residents received at least one vaccine dose during the observation period (Supplementary Fig. 18). The data are available at [inst/data/PNADc_vaxadj_population_210802.csv](https://github.com/inst/data/PNADc_vaxadj_population_210802.csv) in the GitHub repository.

To further investigate the shocks in in-hospital fatality rates before and after Gamma's emergence, we obtained monthly data on healthcare resources reported by healthcare facilities to the National Register of Health Facilities (CNES)⁵³, release 15 September 2021. Data on healthcare resources are mandatory to report by both public and private healthcare facilities and comprised personnel and equipment. Nurses (CBO 2235), nurse assistants (CBO 3222), physiotherapists (CBO 2236), physicians (CBO 2231, 2251, 2252 and 2253) and intensive care physicians (CBO 225150) were summed per month and location according to the 2002 Brazilian Classification of Occupations (Classificação Brasileira de Ocupações (CBO)), and, where possible, records were validated by name and professional health card number. ICU beds summed per month and location reported ICU type II, ICU type III and COVID type II beds. ICU type I beds (code 74) refer to an older standard that is being phased out since 2017 and were not counted. Type II ICU beds (code 75) represent the minimum requirement for severe cases of COVID-19 requiring ventilation. Type III ICU beds (code 76) are, by regulation, reserved for ICU patients with multiple acute failures of vital organs, or to patients at risk of developing them, with an immediate threat to life⁵⁴. Since March 2020, new ICU beds were created to try to minimize the immediate risk of healthcare

system collapse. These ICU beds were intended exclusively for treatment of COVID-19 and are designated COVID-19 type II ICU beds (code 51). At least one microprocessor-controlled lung ventilator must be available for every two ICU beds. Considering that both a ventilator and an ICU bed are necessary for adequate treatment of severe COVID-19, we counted only adult ICU beds with a matched ventilator per month and location, defined as the minimum number of available ventilators (respirador or ventilador) and the number of adult ICU beds in the same healthcare facility that are reported to CNES, which we then aggregated across healthcare facilities in the same location⁵⁵. Critical care beds summed ICU beds and intermediate care beds (code 95), and we considered counts with and without controlling for available reported ventilators. To guard against potential reporting differences or bias in reported bed types²⁰, we also considered monthly counts of available ventilators as resource. The number of reported ventilators (respirador or ventilador, code 64) does not include ventilators already held for ICU or critical care beds. Thus, for each healthcare facility, we counted the number of lung ventilators reported to CNES and added one ventilator for every two reported ICU type II, type III or COVID-19 type II beds, added one ventilator for every three reported intermediate beds and then aggregated across healthcare facilities in the same location. The data are available at [inst/data/IPEA_ICUbeds_physicians_210928.csv](https://github.com/inst/data/IPEA_ICUbeds_physicians_210928.csv) in the GitHub repository.

Statistical analysis of in-hospital fatality rates. To characterize longitudinal trends in in-hospital fatality rates, we considered the age strata

$$\mathcal{A} = \{0-15, 16-29, 30-39, 40-49, 50-59, 60-69, 70-74, 75-79, 80-84, 85-89, 90+\}, \quad (1)$$

to control for age dependence in fatality rates. To capture temporal shocks in fatality rates, all data were aggregated to weeks. In COVID-19-attributable patients with unreported outcomes, deaths were predicted independently in each location, week and age strata based on the fatality rates in COVID-19-attributable patients with observed outcomes in the two previous weeks, assuming data were missing at random over the 3 weeks $w-1$, $w-2$, w in each age group and each location. Empirical fatality rates $z_{l,a,w}$ were defined as the ratio of underreporting-adjusted fatalities in unvaccinated, resident, COVID-19-attributable hospital admissions in location l , age strata a and week w except for weeks with no such hospital admissions. Longitudinal trends $\hat{z}_{l,a,w}$ were obtained by fitting the non-parametric loess smoother as implemented in the R stats package version 4.0.3 with argument $\text{span}=0.3$ to the empirical fatality rates $z_{l,a,w}$ separately for each location and age band, and starting from the first week with non-zero hospital admissions in each age band. To compare fatality rates across cities in a simple statistic while accounting for the substantial differences in age demographics (Supplementary Fig. 18), we calculated age-standardized, weekly in-hospital fatality rates with

$$\hat{z}_{l,w} = \sum_a \frac{n_a^{\text{cities}}}{\sum_b n_b^{\text{cities}}} \hat{z}_{l,a,w}, \quad (2)$$

where $\hat{z}_{l,a,w}$ are the smoothed fatality rates in location l , age strata a and week w , and n_a^{cities} are our 2020 projected population sizes in age band a across the 14 cities (see above). To avoid extrapolation, the smoothed rates (2) were generated onward from the first week for which the $\hat{z}_{l,a,w}$ were defined for all age groups.

We next defined 12 pandemic healthcare pressure indices that quantified hospital demand over time in each location. Demand was defined in terms of all hospital admissions for severe acute respiratory infections (that is, including non-residents, cases caused by other pathogens and vaccinated individuals) and all ICU admissions among patients hospitalized for severe acute respiratory infection. Records were again filtered to exclude out-of-hospital deaths as defined above. The healthcare pressure indices were calculated by considering demand per available healthcare resource over time. To account for the fact that admitted patients remain in care for several weeks, we considered rolling sums of the form

$$x_{l,w}^{3\text{-wk ICU adm per ICU bed}} = \left(\sum_{i=0}^3 h_{l,w+i}^{\text{ICU}} \right) / r_{l,w}^{\text{ICU beds}}, \quad (3)$$

where $h_{l,w}^{\text{ICU}}$ are the number of ICU admissions, and $r_{l,w}^{\text{ICU beds}}$ are the number of ICU beds in location l and week w . Data on resources were available per month. In weeks overlapping months, we used weighted averages of the resources in the corresponding months to define the weekly resources, and, otherwise, we used the monthly values. Supplementary Table 5 provides definitions for all healthcare pressure indices considered. Associations between the healthcare pressure indices and smoothed, age-standardized in-hospital fatality rates were quantified with Pearson correlation coefficients.

Data to account for Gamma's expansion dynamics. To assess fluctuating in-hospital fatality rates in the context of the spatio-temporal expansion of the SARS-CoV-2 Gamma variant, we obtained from GISAID²³ publicly available viral genome sequences across Brazilian states with collection date from 1 November 2020 to 31 March 2021 on 28 June 2021. Acknowledgment tables with GISAID IDs

are available in the acknowledgments_GISAID_Tables directory in the GitHub repository. Records with incomplete collection dates were removed, de-duplicated and classified as Gamma or non-Gamma variants with pangolin version 3.0.6, Pangolearn version 1.2.12, scorpione lineage (<https://github.com/cov-lineages/pangolin>). In total, we retained sequences and metadata from 7,221 samples, most of which were from São Paulo (1,104 viral genomes), with an average of 158 genomes per state. Gamma and non-Gamma frequencies were calculated for each week and location, assuming that the frequency of Gamma in state capitals was similar to the state-level frequency of Gamma in the GISAID data. The data are available at inst/data/genomic_data_210702.csv in the GitHub repository and shown in Supplementary Fig. 19. Supplementary Table 1 reports the weeks in which Gamma was first detected in each location, and Extended Data Fig. 1 shows the proportion of Gamma sequences over time in each location. Throughout, we denote the week index in which Gamma was in each location first detected by $W_l^{\text{detect}-\Gamma}$, the number of sequenced genotypes in location l and collection week w by $s_{l,w}^{\Gamma}$ and the number sequenced genotypes attributed to the Gamma variant with pangolin by $s_{l,w}^{\Gamma}$.

Dating Gamma's emergence. To guide our modeling, we dated the emergence of the SARS-CoV-2 Gamma variant in each location using viral phylogenetic methods based on a subset of 2,212 high-coverage SARS-CoV-2 Gamma genome sequences across the 14 locations under study. This dataset included five sequences that had been recovered from the International Guarulhos Airport in São Paulo. The reference strain WH04 (GISAID EPI_ISL_406801) was appended to the sequence dataset before multiple sequence alignment using MAFFT version 7 (ref. ⁵⁵). After removing untranscribed terminal regions, the resulting multiple sequence alignment had a length of 29,409 nucleotides. Maximum likelihood phylogenetic trees were estimated using IQTree version 2 (ref. ⁵⁶) under the Jukes Cantor (JC69) substitution model⁵⁷. We next used TempEst version 1.5.3 (ref. ⁵⁸) to regress root-to-tip distances against sampling dates and identify data quality and data annotation problems before further phylogenetic analysis. Specifically, we discarded virus genomes characterized by a genetic distance to WH04 of more than 4 standard deviations from the epi-week mean genetic distance to WH04 (ref. ⁵⁹). A total of ten sequences were excluded from subsequent phylogenetic analysis. The GISAID identifiers of the excluded sequences were EPI_ISL_1821206, EPI_ISL_2249444, EPI_ISL_1821208 (earliest available sequence from São Paulo, dated 2020-11-03), EPI_ISL_1821217, EPI_ISL_2249440 (earliest available sequence from Rio de Janeiro, dated 2020-11-18), EPI_ISL_2249443, EPI_ISL_2241496 (earliest available sequence from Paraíba, dated 2020-10-01) and EPI_ISL_1715135, EPI_ISL_1821257 and EPI_ISL_2249437.

Estimating time trees for large alignments can be computationally intractable. Thus, we follow a computation strategy similar to du Plessis et al.⁵⁹ and Gutierrez et al.⁶⁰ that involves (1) estimating an evolutionary rate using a subsample of the genome dataset of interest and (2) using a simpler computational approach to estimate time trees for the complete genome dataset. For step (1), we randomly selected a maximum of 20 sequences per state (except for Paraíba and Rondônia, which had only 15 and nine sequences available, respectively, during the study period). This generated a dataset of 264 genome sequences. Sequences with earliest and latest dates of collection from each state were kept in the alignment to increase temporal signal of the resulting dataset. We used BEAST version 1.10 (ref. ⁶¹) to estimate an evolutionary rate under a Hasegawa–Kishino–Yano⁶² substitution model and a strict molecular clock with a continuous-time Markov chain prior. We used a Bayesian skygrid with ten grid points as a demographic tree prior⁶³. The BEAST.xml file is available at inst/utis/BEAST_thorney_P1.xml in the GitHub repository. Four Markov chain Monte Carlo (MCMC) chains were run for 50 million steps, sampling parameters and trees every 50,000 steps. Convergence of the MCMC chains was assessed using Tracer version 1.7 (ref. ⁶⁴). For step (2), the complete dataset was analyzed using BEAST version 1.10.5 (ref. ⁶⁵) using a newly developed approach that significantly reduces computation time. This approach takes in a rooted phylogenetic maximum likelihood tree (instead of an alignment) and rescales its branches into time units. The likelihood of each branch length is modeled as a Poisson distribution with a mean that is directly proportional to the clock rate^{66,67}. We used a rate of 4.864×10^{-4} substitutions/site/year based on the median clock rate estimate obtained from step (1). We defined a coalescent skygrid prior and used the best-fitting IQTree maximum likelihood tree rooted in TempEst as a starting data tree. Two independent MCMC chains were run for 1,000 million MCMC steps and combined after discarding 10% of the run as burn-in to generate an empirical posterior tree distribution. Convergence was assessed using Tracer version 1.7 (ref. ⁶⁴). We next used a 14-state asymmetric discrete Bayesian molecular clock phylogeographic approach⁶⁸ implemented in BEAST version 1.10.4 (ref. ⁶⁴) to infer ancestral state locations on an empirical distribution of 500 posterior time trees. For sequences with known travel history, we assigned the state of infection instead of state of reporting. We estimated unknown state locations for the sequences collected at the International Guarulhos Airport in São Paulo. We tracked the complete jump history of viral movement events between each pair of states^{69–71}. We used a recently developed tool, the TreeMarkovJumpHistoryAnalyzer, which collects Markov jumps and their timings from a posterior tree distribution with Markov jump histories⁷², available at inst/utis/P1_MJumps_complete_history.xml in the GitHub repository. To date the

most common recent ancestor of the earliest local transmission cluster in each state, we used a customised R script to summarize the posterior probability distribution densities for the earliest time of the introduction leading to two or more descendants in each of the 14 states. The phylogenetically estimated dates of emergence of Gamma in each city are shown in Supplementary Table 1. Throughout, we denote the week of the posterior median estimate with $W_l^{\text{emerge}-\Gamma}$.

Modeling to disentangle factors associated with shocks in in-hospital fatality rates. We developed a Bayesian multi-strain fatality model to disentangle the effects of pre-pandemic geographic inequities, pandemic healthcare pressures and Gamma's in-hospital disease severity on fluctuating COVID-19 in-hospital fatality rates. This section describes the modeling framework, and full details are given in the final section below.

Overall, the model is structured in three components. In the first model component, a logistic function is fitted to the Gamma variant frequency data to estimate the proportion of Gamma infections in location l and week w , which, throughout, we denote by $\alpha_{l,w}$. We here use the phylogenetically derived emergence times of the Gamma variant in each city and specify that $\alpha_{l,w}$ is essentially zero for all weeks before $W_l^{\text{emerge}-\Gamma}$. In the second model component, the proportion of hospitalized patients with Gamma and non-Gamma infections in the weekly hospital admissions are estimated by city, age and week of admission. The model-based attribution of hospital admissions to Gamma and non-Gamma variants is based on the estimated expansion of the Gamma variant in each city through the $\alpha_{l,w}$. In the third model component, we describe the fatality rates in the Gamma-attributable hospital admissions and non-Gamma-attributable hospital admissions through two corresponding regression equations. The regression equations comprise non-parametric location effects, fixed effects associated with the healthcare pressure indices and non-parametric virus variant effects of Gamma-specific disease severity in hospitals. The free parameters of the model, and, in particular, the parameters in the regression equations, can be well-identified from the weekly Gamma variant frequency data (denoted by $s_{l,w}^{\Gamma}$), the weekly COVID-19-attributable hospital admissions (denoted by $h_{l,a,w}^{\text{res}}$) and the number of deaths occurring in the linked, individual-level records of weekly age-specific hospital admissions during follow-up (denoted by $h_{l,a,w}^{\text{res-adj-D}}$) (Extended Data Figs. 1 and 6–9). Recall that the deaths count the observed deaths in patients with known outcome and the expected deaths in patients with unreported outcome, indexed by week w of hospital admission. In the rest of this section, we provide more detail on the second and third component of the model.

In the second model component, the proportion of hospitalized patients with Gamma infection is estimated by city, age and week of admission. To build intuition, we considered modeling the expected values of the hospital admissions $h_{l,a,w}^{\text{res}}$ with

$$\mathbb{E}(h_{l,a,w}^{\text{res}}) = (\alpha_{l,w}\pi_{l,a}^{\Gamma} + (1 - \alpha_{l,w})\pi_{l,a}^{\text{non-}\Gamma})h_{l,w}^{\text{res}}, \quad (4)$$

where $h_{l,w}^{\text{res}}$ is the sum of hospital admissions across age strata; $\pi_{l,a}^{\text{non-}\Gamma}$ is the characteristic age composition of non-Gamma hospital admissions in location l that is independent of time; and $\pi_{l,a}^{\Gamma}$ is the characteristic age composition of Gamma hospital admissions. It is clear that $\pi_{l,a}^{\text{non-}\Gamma}$ can be inferred from patient records when $\alpha_{l,w} \approx 0$ —that is, from before Gamma's expansion—and $\pi_{l,a}^{\Gamma}$ can be inferred from patient records when $\alpha_{l,w} \approx 1$ —that is, from after Gamma's expansion. Across time, the proportion of hospital admissions in age band a is described as a mixture of the Gamma and non-Gamma proportions that is determined by the increasing weights of Gamma's variant frequency $\alpha_{l,w}$ and the decreasing weights of the non-Gamma variant frequencies $1 - \alpha_{l,w}$. The model encodes robustness in the sense that good model fit can be obtained only when the observed age distributions of hospitalized patients shift over time according to Gamma's expansion. Following (4), in a particular age stratum a and week w , the expected number of hospital admissions attributable to Gamma is described by

$$\frac{\alpha_{l,w}\pi_{l,a}^{\Gamma}}{\alpha_{l,w}\pi_{l,a}^{\Gamma} + (1 - \alpha_{l,w})\pi_{l,a}^{\text{non-}\Gamma}}h_{l,w}^{\text{res}}. \quad (5)$$

Equations (4) and (5) are extended in the full model to account for the fact that the age distribution of hospitalized patients is also changing with higher cumulative mortality in older age groups and with prioritized vaccination of older age groups (see below).

In the third model component, we quantify and model the fatality rates in the Gamma-attributable hospital admissions (recall (5)) and non-Gamma-attributable hospital admissions (analogous to (5)) separately. We model in-hospital fatality rates in week w , location l and age group a that are respectively infected with non-Gamma and Gamma variants with the decomposition

$$\zeta_{l,a,w}^{\text{non-}\Gamma} = \text{logit}^{-1}(\eta_{l,a}^{\text{non-}\Gamma} + X_{l,w}\beta_l) \quad (6a)$$

$$\zeta_{l,a,w}^{\Gamma} = \text{logit}^{-1}(\eta_{l,a}^{\text{non-}\Gamma} + \eta_{l,a}^{\Gamma-\text{random-effect}} + X_{l,w}\beta_l), \quad (6b)$$

where $X_{l,w} \in \mathbb{R}^{1 \times P}$ are p standardized healthcare pressure indices in location l and week w and $\beta_l \in \mathbb{R}^P$ are constrained to be non-negative. For each location, we standardized the healthcare pressure indices to zero for the week in which the empirical fatality rates (2) are lowest before Gamma's detection, which was typically at the beginning of the pandemic and observation period. Specifically, we standardized each index according to

$$\tilde{x}_{l,p,w} = \frac{x_{l,p,w} - x_{l,p,\tilde{w}_l}}{\text{s.d.}(x_{l,p,w})}, \quad (7)$$

where $\tilde{w}_l = \arg\min_{w=1:(w_{\text{detect}}-1)} \hat{z}_{l,w}$ and s.d. denotes the standard deviation of the indicator across all weeks in location l , using the notation in (2) and (3). The p regression coefficients β_l were constrained to be positive so that each standardized index of increasing hospital demand pressure could only have an increasing effect on fatality rates when $\beta_l > 0$, or no effect when $\beta_l = 0$, and not offset each other and artifactually increase the effect of another index.

Thus, we can interpret the $\text{logit}^{-1}(\eta_{l,a}^{\text{non-}\Gamma})$ as the lowest observed fatality rate in each location and age group (technically defined before the emergence of Gamma to guard against potential confounders in Belo Horizonte as described in the main text, and except for Belo Horizonte equivalent to over the entire study period) and take ratios of these terms across locations to quantify the effect of geographic inequities (location effect). These ratios measure non-specific baseline differences in fatality rates across the state capitals that are not captured in our healthcare pressure indices. Next, for each location, we can interpret the ratio of $\text{logit}^{-1}(\eta_{l,a}^{\text{non-}\Gamma} + X_{l,w}\beta_l)$ divided by $\text{logit}^{-1}(\eta_{l,a}^{\text{non-}\Gamma})$ as the multiplier to in-hospital fatality rates in week w and age group a that is associated with the increasing healthcare pressure indices (healthcare pressure effect). In (6b), $\eta_{l,a}^{\Gamma-\text{random-effect}}$ are non-parametric random effects that measure age-specific deviations in fatality rates in hospitalized patients attributed to Gamma infection. So, for each location, we can interpret the ratio of $\text{logit}^{-1}(\eta_{l,a}^{\text{non-}\Gamma} + \eta_{l,a}^{\Gamma-\text{random-effect}})$ divided by $\text{logit}^{-1}(\eta_{l,a}^{\text{non-}\Gamma})$ as the multiplier to fatality rates in hospitalized patients that is attributable to Gamma infection versus non-Gamma infection (variant effect in hospitals), controlling for differences in healthcare pressure in the weeks before and after the emergence of Gamma (because the $X_{l,w}\beta_l$ are zeroed) as well as cumulative mortality and vaccination in the full model (see below). We note that the regression model is measuring associations and is not guaranteed to identify causal relationships.

It follows again from (4) that, in a particular age group a and week w , the in-hospital fatality rate in Gamma and non-Gamma patients is described by

$$\zeta_{l,a,w} = \frac{(1-\alpha_{l,w})\pi_{l,a}^{\text{non-}\Gamma}}{\alpha_{l,w}\pi_{l,a}^{\Gamma} + (1-\alpha_{l,w})\pi_{l,a}^{\text{non-}\Gamma}} \zeta_{l,a,w}^{\text{non-}\Gamma} + \frac{\alpha_{l,w}\pi_{l,a}^{\Gamma}}{\alpha_{l,w}\pi_{l,a}^{\Gamma} + (1-\alpha_{l,w})\pi_{l,a}^{\text{non-}\Gamma}} \zeta_{l,a,w}^{\Gamma}. \quad (8)$$

Equation (8) enables us to estimate, for each location, the unknowns in (6) from the longitudinal records of age-specific deaths in the denominator of hospitalized patients with COVID-19 in location l , age group a and week w and expanding variant frequency of Gamma in weekly SARS-CoV-2 sequence data.

Model validation and sensitivity analyses. Concerns on SARS-CoV-2 sequence sample representativeness⁷³ prompted us to re-evaluate our findings using monthly state-level variant frequency data reported by Rede Genômica FioCruz (<http://www.genomahcov.fiocruz.br/dashboard/>). Data on monthly Gamma variant frequencies in each Brazilian federal unit or state between November 2020 and May 2021 were retrieved from the dashboard on 15 June 2021. We again assumed that the variant frequencies reported at state level are representative of the variant frequencies in state capitals. We also considered weekly city-level Gamma variant frequency data from Manaus, Belo Horizonte and São Paulo obtained under controlled sampling frames. In Manaus, samples from PCR-positive residents testing in two private laboratories through nasal and oropharyngeal swabs were selected at random regardless of cycle threshold values for sequencing. The samples were sequenced and processed using the ARTIC bioinformatics pipeline⁷⁴ as described in Faria et al.³. Viral genomes recovered from 147 samples collected between 1 November 2020 and 10 January 2021 had sufficient genome coverage enabling lineage classification with pangolin version 2.2.1 (refs.^{75,76}). In Belo Horizonte, samples were selected at random from PCR-positive residents in three laboratories (Laboratório Hermes Pardini, Laboratório de Biologia Integrativa, UFMG, and Laboratório Municipal de Referência, PBH). The samples were sequenced on the Illumina MiSeq platform and processed using a custom pipeline. Identified mutations were manually inspected, and the sequences were classified using pangolin version 2.2.1 (ref.⁷⁵). In total, 27 samples were classified as Gamma and 47 samples to other lineages. For São Paulo, sequences were generated by the Adolf Lutz Institute, a national public health and reference laboratory for São Paulo State, Brazil, retrieved from GISAID (<https://www.gisaid.org>) for the period 1 November 2020 to 31 March 2021. In total, 76 sequences were analyzed between 1 November 2020 and 31 March 2021. The data are shown in Supplementary Table 6. We found only minor differences in our primary findings depending on what SARS-CoV-2 variant frequency data were used (Supplementary Figs. 9–14).

Given long-term underfunding of Brazil's public healthcare system, we investigated if geographic inequities could be modulated by different proportions

of patients in public and private hospitals and if the strong fluctuations in COVID-19 in-hospital fatality rates are also observed in private hospitals. For São Paulo, we could classify most hospitals as either private or public. We found consistently lower in-hospital fatality rates in private hospitals that, however, fluctuated in synchrony with those in public hospitals, in line with our primary findings (Supplementary Fig. 15).

In Belo Horizonte, the age-standardized COVID-19 in-hospital fatality rates declined over the summer months of 2021 to levels well below those seen during earlier time periods (Fig. 4a). We hypothesized that larger numbers of patients hospitalized in Belo Horizonte may have been vaccinated, with no vaccination record reported to SIVEP-Gripe. To address this possibility, we performed a sub-analysis in which we excluded patients with unreported vaccination status in the SIVEP-Gripe dataset (Supplementary Fig. 2). In the figure, fatality rate estimates are not shown for weeks in which patient denominators were too small. In this sub-analysis, we found larger discrepancies in fatality rates compared to the main analysis only for Belo Horizonte, suggesting that missing data on vaccination status have likely no substantial effect on our overall findings. However, for Belo Horizonte, it is possible that our in-hospital fatality rate estimates are confounded with unreported vaccination status.

The highest age-standardized COVID-19 in-hospital fatality rates were observed in Rio de Janeiro, against the national trend of declining rates in Brazil's South and Southeast macroregions. It is possible that smaller proportions of hospitalized patients with unreported clinical outcomes may have died, and analyses were repeated assuming that all patients with unreported clinical outcomes survived. We found, in comparison to other cities, that Rio de Janeiro's baseline in-hospital fatality rates were, in this sensitivity analysis, considerably lower than in the main analysis but remained overall largest and showed the same strong fluctuations as in the main analysis (Supplementary Fig. 8).

In-hospital fatality rates also depend on which, and under what circumstances, severely ill patients are admitted to hospitals. This prompted us to investigate if the observed fluctuations in COVID-19 fatality rates could, in part, be the result of concomitant changes in the profile of admitted patients. There are limited data on disease severity at time of hospital admission available in SIVEP-Gripe; however, one indicator that can be readily calculated is the time between hospital admission and death in patients with a fatal outcome (Supplementary Fig. 16). In Macapá, Manaus, Porto Alegre and Porto Velho, we found substantially shorter times to death when the number of COVID-19-attributable hospital admissions peaked, suggesting that admitted patients may already have been at a more severe clinical stage when admitted or that, during times of peak demand, healthcare pressure in hospitals both increased fatality rates and led to faster progression to death. Further data on out-of-hospital deaths shows that COVID-19-attributable out-of-hospital deaths typically occurred during times of peak demand, with the exception of Rio de Janeiro (Extended Data Fig. 2). Together, these data suggest that increased healthcare pressure likely acts to shape in-hospital fatality rates through distinct mechanisms, through a combination of both a reduced ability to provide adequate care and an increase in the average severity of admitted patients.

Full statistical model, generated quantities and counterfactuals. We begin by describing the three components of the full statistical model, which were already motivated and introduced above. The first model component describes the temporal expansion of Gamma in hospital admissions through a logistic function and is given by

$$s_{l,w}^{\Gamma} \sim \text{Beta-Binomial}\left(s_{l,w}, \frac{\alpha_{l,w}}{\theta_1}, \frac{1-\alpha_{l,w}}{\theta_1}\right), \quad (9a)$$

$$\alpha_{l,w} = \frac{1}{1 + \exp\left(-\alpha_l^{\text{growth}}(w - \alpha_l^{\text{mid}})\right)} \quad (9b)$$

$$\alpha_l^{\text{growth}} \sim \text{Normal}\left(0, 0.2^2\right) \quad (9c)$$

$$\alpha_l^{\text{mid}} \sim \text{Normal}\left(\alpha_l^{\text{mid-mean}}, 3^2\right) \quad (9d)$$

$$\alpha_{l,1:(w_{\text{merge}}^{\text{merge}}-1)} \sim \text{Normal-ccdf}\left(0, 0.0025^2\right) \quad (9e)$$

$$\theta_1 \sim \text{Exponential}(20), \quad (9f)$$

where the Beta-Binomial is specified in terms of the shape–shape parameterization with mean $s_{l,w}\alpha_{l,w}$ and variance equal to the binomial variance component $s_{l,w}\alpha_{l,w}(1-\alpha_{l,w})$ multiplied by $\left(1 + (s_{l,w}-1)\frac{1}{\theta_1-1}\right)$ to allow for overdispersion in the variant frequency data. Time runs in units of weeks from the start of the first wave until the end of the observation period in each location.

The prior mean for the midpoint of the logistic function, $\alpha_l^{\text{mid-mean}}$, was set to the week in which the ratio $S_{l,w}^{\Gamma}/S_{l,w}$ was closest to 0.5 in location l . We force the variant frequencies of Gamma to close to zero before the week of Gamma's emergence in each location, which is implemented through the informative prior (9e), where normal-cdf denotes the survival function of a normal density. The prior in (9f) peaks at zero and, thus, favors the least complex model with no overdispersion.

In the second model component, we couple (9b) to decompose the COVID-19-attributable hospital admissions $h_{l,a,w}^{\text{res}}$ by admissions with Gamma and non-Gamma variant. We expand on equation (4) to account for demographic changes in the population at risk of severe infection, either through higher cumulative mortality in older ages or through prioritized vaccination of older ages, and denote the population that remains at risk of severe infection in location l , age group a and week w by $n_{l,a,w}^R$. Then, we assumed characteristic per-capita rates $\lambda_{l,a}^{\Gamma}$, $\lambda_{l,a}^{\text{non-}\Gamma}$ of severe infection and hospitalization with Gamma and non-Gamma variants, respectively, and considered modeling the expected values of the hospital admissions $h_{l,a,w}^{\text{res}}$ with

$$\mathbb{E}(h_{l,a,w}^{\text{res}}) = (\alpha_{l,w}\pi_{l,a,w}^{\Gamma} + (1 - \alpha_{l,w})\pi_{l,a,w}^{\text{non-}\Gamma})h_{l,w}^{\text{res}}, \quad (10a)$$

$$\pi_{l,a,w}^{\Gamma} = \lambda_{l,a}^{\Gamma}n_{l,a,w}^R / \sum_a \lambda_{l,a}^{\Gamma}n_{l,a,w}^R, \quad (10b)$$

$$\pi_{l,a,w}^{\text{non-}\Gamma} = \lambda_{l,a}^{\text{non-}\Gamma}n_{l,a,w}^R / \sum_a \lambda_{l,a}^{\text{non-}\Gamma}n_{l,a,w}^R, \quad (10c)$$

and used $\pi_{l,a,w}^{\text{non-}\Gamma}$, $\pi_{l,a,w}^{\Gamma}$ in lieu of $\pi_{l,a}^{\text{non-}\Gamma}$, $\pi_{l,a}^{\Gamma}$ in equations (4), (5) and (8). We specified $n_{l,a,w}^R$ as follows. First, to account for cumulative mortality, we calculated excess deaths based on the all-cause deaths reported by Brazil's Civil Registry (<https://transparencia.registrocivil.org.br/registros>) and subtracted from the population size projections the larger of cumulated excess deaths or all reported COVID-19 deaths in the SIVEP-Gripe database (Supplementary Fig. 6). Second, to account for increasing vaccine protection, we calculated vaccination coverage by vaccine administered in each location, age group and week (Supplementary Figs. 3–5), based on vaccine administration records from the Brazilian Ministry of Health (<https://opendatasus.saude.gov.br/dataset/covid-19-vacinacao>). We then calculated the population at risk of severe infection, $n_{l,a,w}^R$, by subtracting further a proportion of the individuals vaccinated with one or two doses for at least 2 weeks according to the vaccine-specific efficacy values^{77–81} listed in Supplementary Table 7. Following the mean structure of (10), the second model component is given by

$$h_{l,w}^{\text{res}} \sim \text{Dirichlet-Multinomial}(h_{l,w}^{\text{res-sum}}, \phi_{l,w}\pi_{l,w}) \quad (11a)$$

$$\pi_{l,a,w} = \alpha_{l,w}\pi_{l,a,w}^{\Gamma} + (1 - \alpha_{l,w})\pi_{l,a,w}^{\text{non-}\Gamma} \quad (11b)$$

$$\pi_{l,a,w}^{\Gamma} = \text{softmax}(\log \lambda_{l,a}^{\Gamma} + \log n_{l,a,w}^R) \quad (11c)$$

$$\pi_{l,a,w}^{\text{non-}\Gamma} = \text{softmax}(\log \lambda_{l,a}^{\text{non-}\Gamma} + \log n_{l,a,w}^R) \quad (11d)$$

$$\log \lambda_{l,a}^{\Gamma} \sim N(0, 1) \quad (11e)$$

$$\log \lambda_{l,a}^{\text{non-}\Gamma} \sim N(0, 1) \quad (11f)$$

$$\phi_{l,w} = (h_{l,w}^{\text{res-sum}} - 1) / (\theta_2 + 1) \quad (11g)$$

$$\theta_2 \sim \text{Exponential}(20), \quad (11h)$$

where we denote the vector of age-specific hospital admissions in location l and week w by $h_{l,w}^{\text{res}} = (h_{l,a,w}^{\text{res}})_{a \in \mathcal{A}}$ and the vector of the age composition of hospital admissions in location l and week w by $\pi_{l,w} = (\pi_{l,a,w})_{a \in \mathcal{A}}$ again such that $\sum_a \pi_{l,a,w} = 1$. The Dirichlet-Multinomial is in standard sample size-scale parameterization such that the means are given by $h_{l,w}^{\text{res-sum}}\pi_{l,a,w}$ as in (9b). The softmax transformations (11c) and (11d) allow for convenient prior specifications of the log hospital admission rates on the real line and run over age bands a for fixed location l and fixed week w . The scale parameter $\phi_{l,w}$ is conditional on the known $h_{l,w}^{\text{res-sum}}$ re-parameterized into the overdispersion parameter θ_2 , with $\theta_2 > 0$, and the prior on θ_2 in (11h) peaks at zero and favors the least complex model with no overdispersion.

In the third model component, we describe the expected fatality rates in the COVID-19-attributable hospital admissions according to the modeled Gamma and

non-Gamma fatality rates (6) and their corresponding contributions to the overall fatality rates according to Gamma's increasing frequency (8), which is given by

$$h_{l,a,w}^{\text{res-adj-D}} \sim \text{Beta-Binomial}(h_{l,a,w}^{\text{res}}, \zeta_{l,a,w}/\theta_3, (1 - \zeta_{l,a,w})/\theta_3) \quad (12a)$$

$$\zeta_{l,a,w} = \frac{(1 - \alpha_{l,w})\pi_{l,a,w}^{\text{non-}\Gamma}}{\alpha_{l,w}\pi_{l,a,w}^{\Gamma} + (1 - \alpha_{l,w})\pi_{l,a,w}^{\text{non-}\Gamma}}\zeta_{l,a,w}^{\text{non-}\Gamma} + \frac{\alpha_{l,w}\pi_{l,a,w}^{\Gamma}}{\alpha_{l,w}\pi_{l,a,w}^{\Gamma} + (1 - \alpha_{l,w})\pi_{l,a,w}^{\text{non-}\Gamma}}\zeta_{l,a,w}^{\Gamma} \quad (12b)$$

$$\text{logit } \zeta_{l,a,w}^{\text{non-}\Gamma} = \eta_{l,a}^{\text{non-}\Gamma} + X_{l,w}\beta_l \quad (12c)$$

$$\text{logit } \zeta_{l,a,w}^{\Gamma} = \eta_{l,a}^{\text{non-}\Gamma} + \eta_{l,a}^{\Gamma\text{-random-effect}} + X_{l,w}\beta_l \quad (12d)$$

$$\eta_{l,a}^{\text{non-}\Gamma} \sim \text{Normal}(-0.25, 1.5^2) \quad (12e)$$

$$\eta_{l,a}^{\Gamma\text{-random-effect}} \sim \text{Normal}(0, \sigma_{\zeta}^2) \quad (12f)$$

$$\beta_{l,i} \sim \text{Normal}_{[0,\infty)}(0, \kappa_{l,i}^2\tau^2) \quad (12g)$$

$$\kappa_{l,i} \sim \text{Half-Cauchy}(0, 1) \quad (12h)$$

$$\tau \sim \text{Half-Cauchy}(0, 0.01) \quad (12i)$$

$$\sigma_{\zeta} \sim \text{Exponential}(2) \quad (12j)$$

$$\theta_3 \sim \text{Exponential}(100), \quad (12k)$$

where $w = 1, \dots, W_l$. Importantly, we note that the deaths $h_{l,a,w}^{\text{res-adj-D}}$ in (12a) are derived from the individual-level line list of hospital admissions in week w , adjusted only for underreporting, and so $h_{l,a,w}^{\text{res-adj-D}}$ counts the deaths in exactly the $h_{l,a,w}^{\text{res}}$ individual patients who were admitted in week w . The Beta-Binomial is in the shape-shape parameterization with mean $h_{l,a,w}^{\text{res}}\zeta_{l,a,w}$ and variance equal to the binomial variance component $h_{l,a,w}^{\text{res}}\zeta_{l,a,w}(1 - \zeta_{l,a,w})$ multiplied by $(1 + (h_{l,a,w}^{\text{res}} - 1)\frac{1}{\theta_3 - 1 + 1})$ to allow for overdispersion. The priors in (12e) were chosen to place the non-Gamma in-hospital fatality rate around the empirically observed range. In (12f), we model the Gamma in-hospital fatality rate as a random effect around the non-Gamma in-hospital fatality rate. In the model, we conservatively sought to favor no dependence of in-hospital fatality rates on the hospital pressure indices, which we implemented using the horseshoe-type shrinkage prior in (12g–12i). The prior in (12k) peaks at zero and favors the least complex model with no overdispersion.

The model described through equations (9)–(12) was implemented in the Stan probabilistic computing language, is available at `inst/stan-models/age_hfr_210719d.stan` in the GitHub repository and was independently fitted to data from each location using `cmdstanr` version 0.3.0.9 (refs. ^{82,83}). Because inferences were performed separately for each location, the estimates from each location provide independent support into the inferred relationships among in-hospital fatality rates, healthcare inequities and healthcare pressure. Each inference was conducted in four Hamiltonian Monte Carlo chains, each over 500 warmup iterations, and 50,500 sampling iterations. The smallest bulk effective sample size was 1,687.

From the Monte Carlo samples of the joint posterior distribution of the fitted Bayesian multi-strain fatality model, we generate the following quantities. We calculate the expected, COVID-19-attributable hospital admissions among residents in location l , age band a and week w for non-Gamma and Gamma variants that had no evidence of vaccination before hospitalization, respectively, by

$$h_{l,a,w}^{\text{res-non-}\Gamma} = (1 - \alpha_{l,w})\pi_{l,a,w}^{\text{non-}\Gamma}h_{l,a,w}^{\text{res}} \quad (13a)$$

$$h_{l,a,w}^{\text{res-}\Gamma} = \alpha_{l,w}\pi_{l,a,w}^{\Gamma}h_{l,a,w}^{\text{res}}, \quad (13b)$$

where $h_{l,a,w}^{\text{res}}$ are observed and $\alpha_{l,w}$, $\pi_{l,a,w}^{\text{non-}\Gamma}$, $\pi_{l,a,w}^{\Gamma}$ are from the joint posterior. The expected, COVID-19-attributable hospital admissions among residents in location l , age band a and week w across all variants are

$$h_{l,a,w}^{\text{res-all}} = h_{l,a,w}^{\text{res-non-}\Gamma} + h_{l,a,w}^{\text{res-}\Gamma}. \quad (14)$$

We, thus, have that the expected share of age group a among hospital admissions among residents of location l in week w with non-Gamma variants is $\frac{h_{l,a,w}^{\text{res-non-}\Gamma}}{\sum_b h_{l,b,w}^{\text{res-non-}\Gamma}} = \pi_{l,a,w}^{\text{non-}\Gamma}$ and similarly for Gamma. The expected share of age group a among hospital admissions among residents of location l in week w across all variants is $\pi_{l,a,w} = (1 - \alpha_{l,w}) \pi_{l,a,w}^{\text{non-}\Gamma} + \alpha_{l,w} \pi_{l,a,w}^{\Gamma}$. We calculate the expected, COVID-19-attributable deaths among hospital admissions in residents in location l , age band a and week w for non-Gamma and Gamma variants, respectively, by

$$h_{l,a,w}^{\text{res-non-}\Gamma-\text{D}} = (1 - \alpha_{l,w}) \pi_{l,a,w}^{\text{non-}\Gamma} h_{l,a,w}^{\text{res-non-}\Gamma} \quad (15a)$$

$$h_{l,a,w}^{\text{res-}\Gamma-\text{D}} = \alpha_{l,w} \pi_{l,a,w}^{\Gamma} h_{l,a,w}^{\text{res-}\Gamma} \quad (15b)$$

where $h_{l,a,w}^{\text{res}}$ are observed and $\alpha_{l,w}$, $\pi_{l,a,w}^{\text{non-}\Gamma}$, $\pi_{l,a,w}^{\Gamma}$, $\zeta_{l,a,w}^{\text{non-}\Gamma}$, $\zeta_{l,a,w}^{\Gamma}$ are from the joint posterior. The expected, COVID-19-attributable deaths among hospital admissions in residents in location l , age band a and week w for all variants are

$$h_{l,a,w}^{\text{res-all-D}} = h_{l,a,w}^{\text{res-non-}\Gamma-\text{D}} + h_{l,a,w}^{\text{res-}\Gamma-\text{D}}. \quad (16)$$

To compare COVID-19 in-hospital fatality rates across locations, we define the overall in-hospital fatality rate in location l and week w in an age-standardized population that adjusts for differences in age composition across locations. Specifically, we calculate

$$\zeta_{l,w}^{\text{age-std}} = \sum_a \frac{n_a^{\text{cities}}}{\sum_b n_b^{\text{cities}}} \zeta_{l,a,w}, \quad (17)$$

where n_a^{cities} is the population size in age band a across all cities considered, and $\zeta_{l,a,w}$ is from the joint posterior. Then, for each location, we define the week w^* with lowest in-hospital fatality rate as the week that minimizes the posterior median of (17),

$$w_l^* = \underset{w \in 1:W_l^{\text{detect-}\Gamma}}{\text{argmin}} \left(\text{posterior median of } \zeta_{l,w}^{\text{age-std}} \right), \quad (18)$$

and calculate the lowest, age-standardized COVID-19 in-hospital fatality rates before the first detection of Gamma through

$$\zeta_l^{\text{lowest}} = \zeta_{l,w_l^*}^{\text{age-std}}. \quad (19)$$

We recall that the healthcare pressure indices are standardized and evaluate to zero in the reference week of each location—that is, the week before the first detection of Gamma with lowest empirical, age-standardized in-hospital fatality rate. The week w_l^* typically corresponds to the week with lowest empirical, age-standardized in-hospital fatality rate, and so ζ_l^{lowest} is evaluated when the healthcare pressure effect $X_{l,w} \beta_l$ is zero. The estimated Gamma frequencies $\alpha_{l,w}$ are, of course, also very small before the first detection of Gamma, and so the lowest, age-standardized COVID-19 in-hospital fatality rate are to good approximation given by

$$\zeta_l^{\text{lowest}} \approx \sum_a \frac{n_a^{\text{cities}}}{\sum_b n_b^{\text{cities}}} \logit^{-1} \left(\eta_{l,a}^{\text{non-}\Gamma} \right), \quad (20)$$

where $\eta_{l,a}^{\text{non-}\Gamma}$ are the intercept terms in our regression (6) and from the joint posterior. Then, to compare (19) across locations, we find the location with overall lowest age-standardised in-hospital fatality rate by

$$l^* = \underset{l}{\text{argmin}} \zeta_l^{\text{lowest}}, \quad (21)$$

and compute for all other locations l the ratio

$$\zeta_l^{\text{lowest-ratio}} = \zeta_l^{\text{lowest}} / \zeta_{l^*}^{\text{lowest}}. \quad (22)$$

We interpret (22) as the location effect on COVID-19 in-hospital fatality rates. Because of (20), the location effect does not include contributions attributable to the healthcare pressure indices ($X_{l,w} \beta_l$) nor any contributions attributable to the non-parametric Gamma effects ($\eta_{l,a}^{\Gamma}$) on in-hospital fatality rates.

To compare time trends to in-hospital fatality rates in each location, we calculate for each location the multiplicative effect of changes in healthcare demand and resources in week w in location l by

$$\zeta_{l,w}^{\text{multiplier}} = \sum_a \frac{n_a^{\text{cities}}}{\sum_b n_b^{\text{cities}}} \left(\zeta_{l,a,w}^{\text{non-}\Gamma} / \zeta_{l,a,w_l^*}^{\text{non-}\Gamma} \right), \quad (23)$$

where $\zeta_{l,a,w}^{\text{non-}\Gamma}$ are from the joint posterior. Recalling equation (6a), we have

$$\zeta_{l,w}^{\text{multiplier}} \approx \sum_a \frac{n_a^{\text{cities}}}{\sum_b n_b^{\text{cities}}} \frac{\logit^{-1} \left(\eta_{l,a}^{\text{non-}\Gamma} + X_{l,w} \beta_l \right)}{\logit^{-1} \left(\eta_{l,a}^{\text{non-}\Gamma} \right)}. \quad (24)$$

Here, the approximation is because the Gamma frequencies $\alpha_{l,w}$ are very small but not exactly zero and because the week in which the loess-smoothed fatality rates are lowest may not exactly coincide with the week w_l^* in which the model-based fatality rates are lowest. We interpret (23) as the healthcare pressure effect on COVID-19 in-hospital fatality rates. Because of (24), the healthcare pressure effect does not include contributions attributable to the non-parametric Gamma effects ($\eta_{l,a}^{\Gamma}$) on in-hospital fatality rates and corresponds to the multiplier to the minimum fatality rates in each location that is associated with the healthcare pressure indices ($X_{l,w} \beta_l$).

Finally, we describe the effect of Gamma on in-hospital fatality rates in the model. Standardizing across age bands, we calculate the ratio in Gamma versus non-Gamma in-hospital fatality rates in location l by

$$\zeta_l^{\Gamma-\text{ratio}} = \sum_a \frac{n_a^{\text{cities}}}{\sum_b n_b^{\text{cities}}} \zeta_{l,a,w_l^*}^{\Gamma} / \zeta_{l,a,w_l^*}^{\text{non-}\Gamma}, \quad (25)$$

where $\zeta_{l,a,w_l^*}^{\Gamma}$, $\zeta_{l,a,w_l^*}^{\text{non-}\Gamma}$ are from the joint posterior. We interpret (25) as the Gamma effect on in-hospital fatality rates. It is again helpful to recall equation (6), which shows that we can approximate the Gamma effect through

$$\zeta_l^{\Gamma-\text{ratio}} \approx \sum_a \frac{n_a^{\text{cities}}}{\sum_b n_b^{\text{cities}}} \frac{\logit^{-1} \left(\eta_{l,a}^{\text{non-}\Gamma} + \eta_{l,a}^{\Gamma} \right)}{\logit^{-1} \left(\eta_{l,a}^{\text{non-}\Gamma} \right)}. \quad (26)$$

The ratio $\zeta_l^{\Gamma-\text{ratio}}$ does not include contributions attributable to the healthcare pressure indices ($X_{l,w} \beta_l$) and corresponds to the multiplier to the minimum fatality rates in each location that is associated with the non-parametric Gamma effects ($\eta_{l,a}^{\Gamma}$).

To quantify the effect that the observed fluctuations in COVID-19-attributable in-hospital rates had on the death toll in the 14 state capitals, we performed two counterfactual analyses. The aim of the first counterfactual (Scenario 1) was to estimate how many COVID-19-attributable deaths could have been avoided with sufficient healthcare resources so that healthcare pressures would not have resulted in shocks in in-hospital fatality rates in each city. We implemented Scenario 1 by predicting deaths in each city under the minimum in-hospital fatality rate that was observed in each age group in that city. Specifically, for each location l , we considered the estimated age-specific in-hospital fatality rates (8) in the week (18) and computed

$$h_l^{\text{hyp1-res-D}} = \sum_{w=1}^{W_l} \sum_{a \in \mathcal{A}} h_{l,a,w}^{\text{res}} \zeta_{l,a,w_l^*}, \quad (27)$$

where the week indices range over the entire observation period. We define the expected COVID-19-attributable deaths that could have been avoided in the absence of healthcare pressures in location l during the observation period relative to this hypothetical scenario by

$$h_l^{\text{hyp1-avoidable-D}} = \left(\sum_{w=1}^{W_l} \sum_{a \in \mathcal{A}} h_{l,a,w}^{\text{res-adj-D}} \right) - h_l^{\text{hyp1-res-D}}. \quad (28)$$

Similarly, we define the expected percentage reduction in COVID-19-attributable deaths relative to this hypothetical scenario by

$$p_l^{\text{hyp1-avoidable-D}} = 1 - \frac{h_l^{\text{hyp1-res-D}}}{\sum_{w=1}^{W_l} \sum_{a \in \mathcal{A}} h_{l,a,w}^{\text{res-adj-D}}}. \quad (29)$$

The aim of the second counterfactual (Scenario 2) was to estimate how many COVID-19-attributable deaths could have been avoided with sufficient healthcare resources and without healthcare inequities across the cities. We implemented Scenario 2 by predicting deaths in each city under the minimum in-hospital fatality rate seen across all cities, which we observed in Belo Horizonte. Specifically, we considered the location l^* in which we found the lowest age-standardized in-hospital fatality rate before Gamma's detection in each location

$$l^* = \underset{l}{\text{argmin}} \left(\min_{w \in 1:W_l^{\text{detect-}\Gamma}} \left(\text{posterior median of } \zeta_{l,w}^{\text{age-std}} \right) \right) \quad (30)$$

and computed

$$h_l^{\text{hyp2-res-D}} = \sum_{w=1}^{W_l} \sum_{a \in \mathcal{A}} h_{l,a,w}^{\text{res}} \zeta_{l^*,a,w_l^*}, \quad (31)$$

where, again, the week indices range over the entire observation period. In analogy to the first counterfactual, we then calculate

$$h_l^{\text{hyp2-avoidable-D}} = \left(\sum_{w=1}^{W_l} \sum_{a \in \mathcal{A}} h_{l,a,w}^{\text{res-adj-D}} \right) - h_l^{\text{hyp2-res-D}}, \quad (32)$$

and then the expected percentage reduction

$$p_l^{\text{hyp2-avoidable-D}} = 1 - \frac{h_l^{\text{hyp2-res-D}}}{\sum_{w=1}^{W_l} \sum_{a \in A} h_{l,a,w}^{\text{res-adj-D}}} \quad (33)$$

Reporting Summary. Further information on research design is available in the Nature Research Reporting Summary linked to this article.

Data availability

All data necessary for the replication of our results are available at https://github.com/CADDE-CENTRE/covid19_brazil_hfr (<https://doi.org/10.5281/zenodo.6373425>). These datasets were derived from the following public domain resources: the SIVEP-Gripe platform (<https://opendatasus.saude.gov.br/dataset/srag-2020>), <https://opendatasus.saude.gov.br/dataset/srag-2021-e2022>); the Brazilian Civil Registry (<https://transparencia.registrocivil.org.br/>); the Brazilian Ministry of Health (<https://opendatasus.saude.gov.br/dataset/covid-19-vacinacao>); the National Household Sample Survey COVID-19 (<https://www.ibge.gov.br/estatisticas/sociais/populacao/9171-pesquisa-nacional-poramostra-de-domicilios-continua-mensal.html?&t=o-que-e>); and Brazil's National Register of Health Facilities (<https://datasus.saude.gov.br/transferecia-de-arquivos/>). Data from the Brazilian Civil Registry were accessed on 9 August 2021 through <https://github.com/capyvara/brazil-civil-registry-data>. The downloaded and processed versions are also available in our GitHub repository at [inst/data/SIVEP_hospital_31-01-2022-all.rds](https://github.com/inst/data/SIVEP_hospital_31-01-2022-all.rds); [inst/data/registry_covid_detailed_09-08-2021.csv](https://github.com/inst/data/registry_covid_detailed_09-08-2021.csv); [inst/data/aggregated_vaccinations_210805.rds](https://github.com/inst/data/aggregated_vaccinations_210805.rds); [inst/data/PNADc_populationpyramids_210617.csv](https://github.com/inst/data/PNADc_populationpyramids_210617.csv); [inst/data/genomic_data_210702.csv](https://github.com/inst/data/genomic_data_210702.csv); and [inst/data/IPEA_ICUbeds_physicians_210928.csv](https://github.com/inst/data/IPEA_ICUbeds_physicians_210928.csv).

Code availability

The code necessary to reproduce the analysis are available in the GitHub repository at https://github.com/CADDE-CENTRE/COVID-19_brazil_hfr (<https://doi.org/10.5281/zenodo.6373425>).

References

1. Pesquisa Nacional por Amostra de Domicílios - PNAD COVID19 (IBGE, 2020); <https://www.ibge.gov.br/estatisticas/sociais/trabalho/27946-divulgacao-s-emanal-pnad-covid1.html?&t=micrordados>
2. Cadastro Nacional de Estabelecimentos de Saúde. DataSUS <https://datasus.saude.gov.br/transferecia-de-arquivos/> (2021).
3. Resolution No. 2.271 of February 14, 2020 (2020); <https://www.in.gov.br/web/dou/-/resolucao-n-2.271-de-14-de-fevereiro-de-2020-253606068>
4. Katoh, K. & Standley, D. M. MAFFT multiple sequence alignment software version 7: improvements in performance and usability. *Mol. Biol. Evol.* **30**, 772–780 (2013).
5. Minh, B. Q. et al. IQ-TREE 2: new models and efficient methods for phylogenetic inference in the genomic era. *Mol. Biol. Evol.* **37**, 1530–1534 (2020).
6. Jukes, T. H. et al. in *Mammalian Protein Metabolism* (eds Munro, H. N. & Allison, J. B.) 21–132 (Elsevier, 1969).
7. Rambaut, A., Lam, T. T., Max Carvalho, L. & Pybus, O. G. Exploring the temporal structure of heterochronous sequences using TempEst (formerly Path-O-Gen). *Virus Evol.* **2**, vew007 (2016).
8. du Plessis, L. et al. Establishment and lineage dynamics of the SARS-CoV-2 epidemic in the UK. *Science* **371**, 708–712 (2021).
9. Gutierrez, B. et al. Genomic epidemiology of SARS-CoV2 transmission lineages in Ecuador. *Virus Evol.* **7**, veab051 (2021).
10. Suchard, M. A. et al. Bayesian phylogenetic and phylodynamic data integration using BEAST 1.10. *Virus Evol.* **4**, vey016 (2018).
11. Hasegawa, M., Kishino, H. & Yano, T.-A. Dating of the human–ape splitting by a molecular clock of mitochondrial DNA. *J. Mol. Evol.* **22**, 160–174 (1985).
12. Hill, V. & Baele, G. Bayesian estimation of past population dynamics in BEAST 1.10 using the Skygrid coalescent model. *Mol. Biol. Evol.* **36**, 2620–2628 (2019).
13. Rambaut, A., Drummond, A. J., Xie, D., Baele, G. & Suchard, M. A. Posterior summarization in Bayesian phylogenetics using tracer 1.7. *Syst. Biol.* **67**, 901–904 (2018).
14. McCrone, J. T. BEAST v1.10.5 pre-release of ThorneTreeLikelihood v0.1.1. *GitHub* https://github.com/beast-dev/beast-mcmc/releases/tag/v1.10.5pre_thorne_v0.1.1 (2021).
15. Volz, E. M. & Frost, S. D. W. Scalable relaxed clock phylogenetic dating. *Virus Evol.* **3**, vex025 (2017).
16. Didelot, X., Siveroni, I. & Volz, E. M. Additive uncorrelated relaxed clock models for the dating of genomic epidemiology phylogenies. *Mol. Biol. Evol.* **38**, 307–317 (2021).
17. Lemey, P., Rambaut, A., Drummond, A. J. & Suchard, M. A. Bayesian phylogeography finds its roots. *PLoS Comput. Biol.* **5**, e1000520 (2009).

18. Minin, V. N. & Suchard, M. A. Counting labeled transitions in continuous-time Markov models of evolution. *J. Math. Biol.* **56**, 391–412 (2008).
19. Minin, V. N. & Suchard, M. A. Fast, accurate and simulation-free stochastic mapping. *Phil. Trans. R. Soc. B* **363**, 3985–3995 (2008).
20. O'Brien, J. D., Minin, V. N. & Suchard, M. A. Learning to count: robust estimates for labeled distances between molecular sequences. *Mol. Biol. Evol.* **26**, 801–814 (2009).
21. Lemey, P. et al. Untangling introductions and persistence in COVID-19 resurgence in Europe. *Nature* **595**, 713–717 (2021).
22. *Genomic Sequencing of SARS-CoV-2: A Guide to Implementation for Maximum Impact on Public Health* (WHO, 2021); <https://www.who.int/publications/i/item/9789240018440>
23. artic-network/fieldbioinformatics. *GitHub* <https://github.com/artic-network/fieldbioinformatics> (2022).
24. O'Toole, Á., Hill, V., McCrone, J. T., Scher, E. & Rambaut, A. Pangolin COVID-19 Lineage Assigner (2022); <https://pangolin.cog-uk.io/>
25. Rambaut, A. et al. A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology. *Nat. Microbiol.* **5**, 1403–1407 (2020).
26. Ranzani, O. T. et al. Effectiveness of the CoronaVac vaccine in older adults during a gamma variant associated epidemic of COVID-19 in Brazil: test negative case–control study. *BMJ* **374**, n2016 (2021).
27. Voysey, M. et al. Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. *Lancet* **397**, 881–891 (2021).
28. Madhi, S. A. et al. Efficacy of the ChAdOx1 nCoV-19 COVID-19 vaccine against the B.1.351 variant. *N. Engl. J. Med.* **384**, 1885–1898 (2021).
29. Clemens, S. A. C. et al. Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 lineages circulating in Brazil. *Nat. Commun.* **12**, 5861 (2021).
30. Khoury, D. S. et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2-infection. *Nat. Med.* **27**, 1205–1211 (2021).
31. Carpenter, B. et al. Stan: a probabilistic programming language. *J. Stat. Softw.* **76**, 1–32 (2017).
32. Hoffman, M. D. & Gelman, A. The No-U-Turn sampler: adaptively setting path lengths in Hamiltonian Monte Carlo. *J. Mach. Learn. Res.* **15**, 1593–1623 (2014).

Acknowledgements

We thank all contributors to GISAID for making SARS-CoV-2 sequence data and metadata publicly available, as listed in Methods; all contributors to Rede Genômica Fiocruz for making SARS-CoV-2 variant frequency data publicly available; all members of the CADDE network for their comments throughout the project and earlier versions of the manuscript; O. G. Pybus, A. Rambaut and J. T. McCrone for their insightful comments on SARS-CoV-2 phylogenetic analyses; and the Imperial College Research Computing Service (<https://doi.org/10.14469/hpc/2232>) for providing the computational resources to perform this study. This study was supported by the Medical Research Council–São Paulo Research Foundation (FAPESP) CADDE partnership award (MR/S0195/1 and FAPESP18/143890) (<https://caddecetre.org>), the Bill & Melinda Gates Foundation (INV-034540 and INV-034652) and the EPSRC through the EPSRC Centre for Doctoral Training in Modern Statistics and Statistical Machine Learning at Imperial and Oxford (EP/S023151/1). The authors acknowledge funding from the MRC Centre for Global Infectious Disease Analysis (MR/R015600/1), jointly funded by the UK Medical Research Council (MRC) and the UK Foreign, Commonwealth & Development Office (FCDO), under the MRC/FCDO Concordat agreement, and also part of the EDCTP2 programme supported by the European Union. R.S.A. acknowledges support from the Rede Coronômica BR MCTI/FINEP affiliated to RedeVirus/MCTI (FINEP 01.20.0029.000462/20, CNPq 404096/20204), from CNPq (312688/2017-2 and 439119/2018-9), from MEC/CAPES (14/2020 - 23072.211119/2020-10) and from FINEP (0494/20 01.20.0026.00). S.B. acknowledges support from UK Research and Innovation (MR/V038109/1), the MRC (MR/R015600/1), the Novo Nordisk Young Investigator Award (NNF20OC0059309), the Danish National Research Foundation via a chair position and the NIHR Health Protection Research Unit in Modelling Methodology. L.S.B. acknowledges support from Inova Fiocruz (48401485034116). D.S.C. acknowledges support from the Clarendon Fund, the University of Oxford Department of Zoology and Merton College. N.R.F. acknowledges support from the Wellcome Trust and the Royal Society (Sir Henry Dale Fellowship, 204311/Z/16/Z). S.F. acknowledges support from the EPSRC (EP/V002910/2). C.A.P. acknowledges support from FAPESP (2019/21858-0) and Fundação Faculdade de Medicina e Coordenação de Aperfeiçoamento de Pessoal de Nível Superior Brasil (CAPES). O.T.R. acknowledges support from the Instituto de Salud Carlos III (Sara Borrell fellowship, CD19/00110), from the Spanish Ministry of Science and Innovation and State Research Agency through the 'Centro de Excelencia Severo Ochoa 2019-2023' program (CEX2018-000806-S) and from the 'Generalitat de Catalunya' through the CERCA program. O.R. acknowledges support from the Bill & Melinda Gates Foundation (OPP1175094) and the Medical Research Council (MR/V038109/1). R.P.S. acknowledges support from the Rede Coronômica BR MCTI/FINEP affiliated with RedeVirus/MCTI (FINEP 01.20.0029.000462/20 and CNPq 404096/2020-4), from CNPq (310627/2018-4), from

MEC/CAPES (14/2020 – 23072.211119/2020-10), from FINEP (0494/20 01.20.0026.00) and from FAPEMIG (APQ-00475-20). W.M.S. acknowledges support from the Global Virus Network Fellowship and the National Institutes of Health (AI12094). C.W. acknowledges support from the Medical Research Council (Doctoral Training Partnership Studentship 1975152). P.L. acknowledges support from the European Research Council (grant 725422).

Author contributions

O.R. conceived the study. E.C.S., N.R.F., S.B. and O.R. oversaw the study. A. Brizzi, L.M.S.S., I.H., C.A.P., W.M.S., R.S.A., H.J.A., L.J.T.A., J.L.F.A., R.M.S., P.L.C.F., V.E.V.G., D.M.B., D.C.Q. and R.S. oversaw and performed data collection. A. Brizzi, C.W., L.M.S.S., I.H., C.A.P. and W.M.S. led the analysis. A. Blenkinsop, L.F.B., D.C., M.C.C., S.S.C., J.C., A.A.D.S.S., C.D., S.F., B.G., P.L., A.S.L., T.M., X.M., S.M., M.M., R.G.M., F.R.R.M., B.N., R.H.M.P., O.R., R.P.S., E.S., R.S., X.X. and N.R.F. contributed to the analysis. All authors discussed the results and contributed to the revision of the final manuscript.

Competing interests

The authors declare no competing interests.

Additional information


Extended data is available for this paper at <https://doi.org/10.1038/s41591-022-01807-1>.

Supplementary information The online version contains supplementary material available at <https://doi.org/10.1038/s41591-022-01807-1>.


Correspondence and requests for materials should be addressed to Ester C. Sabino, Nuno R. Faria, Samir Bhatt or Oliver Ratmann.

Peer review information *Nature Medicine* thanks Jon Zelner, Silvana Nair Leite and Virginia Pitzer for their contribution to the peer review of this work. Primary Handling Editor: Jennifer Sargent, in collaboration with the *Nature Medicine* team.


Reprints and permissions information is available at www.nature.com/reprints.




Extended Data Fig. 1 | Spatiotemporal expansion of the SARS-CoV-2 Gamma variant across Brazil. SARS-CoV-2 genome sequences were obtained from the GISAID repository²³ along with confirmed lineage assignments. The frequency of the Gamma variant (dots) in weekly SARS-CoV-2 genome sequence counts (size of dots) is shown along with posterior median estimates of Gamma's variant frequencies (black line) under the Bayesian multi-strain fatality model and 95% credible intervals (grey ribbon).



Extended Data Fig. 2 | Underreporting-adjusted COVID-19 attributable deaths. Reported COVID-19 attributable deaths in the SIVEP-Gripe platform were adjusted for in-hospital underreporting, by counting a proportion of hospitalised patients with as of yet unreported outcome as fatal, and for likely out-of-hospital under-reporting, by comparison against population excess deaths derived from all-cause mortality data of the Brazilian Civil Registry (Supplementary Information). The date of Gamma's first detection in each city is shown as a vertical dotted line.




Extended Data Fig. 3 | Time trends in age-specific COVID-19 in-hospital fatality rates. Weekly, age-specific COVID-19 in-hospital fatality rates are shown as dots, and non-parametric loess mean estimates of time trends are shown as block solid line along with 95% confidence intervals as grey ribbon. The date of Gamma's first detection is indicated with vertical black lines. Data are shown for Goiânia (**a**), Natal (**b**), Rio de Janeiro (**c**), and São Paulo (**d**).




Extended Data Fig. 4 | See next page for caption.

Extended Data Fig. 4 | Time evolution of pandemic healthcare pressure indices, part 1. SARI admissions in this and the following two weeks per hospital resource are shown in colour, with y-axis on the left. In **(a)**, demand per critical care bed is shown, and in **(b)** demand per physician. Non-parametric mean estimates of age-standardised COVID-19 in-hospital fatality rates are shown in black, with 95% confidence intervals as grey ribbons, and y-axis on the right. Pearson correlation coefficients (r) are shown in the upper left corner, and dates of Gamma's first detection as vertical black lines.




Extended Data Fig. 5 | See next page for caption.


Extended Data Fig. 5 | Time evolution of pandemic healthcare pressure indices, part 2. ICU admissions in this and the following two weeks per hospital resource are shown in colour, with y-axis on the left. In **(a)**, demand per ventilator is shown, and in **(b)** demand per intensive care specialist. Non-parametric mean estimates of age-standardised COVID-19 in-hospital fatality rates are shown in black, with 95% confidence intervals as grey ribbons, and y-axis on the right. Pearson correlation coefficients (r) are shown in the upper left corner, and dates of Gamma's first detection as vertical lines.




Extended Data Fig. 6 | Estimated COVID-19 attributable hospital admissions by SARS-CoV-2 variant. Posterior median estimates of hospital admissions among residents in each location, that are attributed to non-Gamma variants are shown for each age band (color) in lighter shades, while those for the Gamma variant are shown in darker shades. Estimates are derived using the Bayesian multi-strain fatality model. Locations are shown across facets. The date of Gamma's detection is shown as a grey vertical line. Observed weekly hospital admissions in residents are shown as black dots.



Extended Data Fig. 7 | Estimated COVID-19 attributable deaths in hospitals by SARS-CoV-2 variant. Posterior median estimates of deaths following hospital admissions of residents in each location, that are attributed to non-Gamma variants are shown for each age band (color) in lighter shades, while those for the Gamma variant are shown in darker shades. Estimates are derived using the Bayesian multi-strain fatality model. Locations are shown across facets. The date of Gamma's detection is shown as a grey vertical line. Observed weekly deaths following hospital admissions in residents are shown as black dots.



Extended Data Fig. 8 | Model fits to age-specific COVID-19 in-hospital fatality rates. Weekly, age-specific in-hospital fatality rates are shown as dots. Posterior median estimates of the expected in-hospital fatality rates across variants from the Bayesian multi-strain fatality model, Equation. (8), are shown on the y-axis (black line) along with 95% credible intervals (grey ribbon). The expected in-hospital fatality rates of non-Gamma variants, Equation (6a), are shown as dotted line. The date of Gamma's first detection is indicated as a vertical line. Data are shown for Goiânia (a), Manaus (b), Rio de Janeiro (c), and São Paulo (d).



Extended Data Fig. 9 | Model fits of the expected age composition of COVID-19 attributable hospital admissions. Posterior median estimates of the expected age composition of hospital admissions in each location, age band, and week, obtained with the Bayesian multi-strain fatality model are shown on the y-axis as a black line along with 95% credible intervals. Time trends are shown by week of hospital admission (x-axis). The empirical proportions are shown as dots. Data are shown for Goiânia (**a**), Manaus (**b**), Rio de Janeiro (**c**), and São Paulo (**d**).

Reporting Summary

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our [Editorial Policies](#) and the [Editorial Policy Checklist](#).

Statistics

For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.

- | | |
|-------------------------------------|--|
| n/a | Confirmed |
| ☐ | ☒ The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement |
| ☒ | ☐ A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly |
| ☒ | ☐ The statistical test(s) used AND whether they are one- or two-sided
<i>Only common tests should be described solely by name; describe more complex techniques in the Methods section.</i> |
| ☐ | ☒ A description of all covariates tested |
| ☐ | ☒ A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons |
| ☐ | ☒ A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals) |
| ☒ | ☐ For null hypothesis testing, the test statistic (e.g. F , t , r) with confidence intervals, effect sizes, degrees of freedom and P value noted
<i>Give P values as exact values whenever suitable.</i> |
| ☐ | ☒ For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings |
| ☒ | ☐ For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes |
| ☐ | ☒ Estimates of effect sizes (e.g. Cohen's d , Pearson's r), indicating how they were calculated |

Our web collection on [statistics for biologists](#) contains articles on many of the points above.

Software and code

Policy information about [availability of computer code](#)

- | | |
|-----------------|--|
| Data collection | No primary data collection was carried out for these analyses. |
| Data analysis | <p>All code used for the analyses is publicly available at: https://github.com/CADDE-CENTRE/covid19_brazil_hfr/ (DOI:10.5281/zenodo.6373425). The following packages were used within R version 4.0.3: (cmdstan v0.3.0.9, stats v4.0.3). Software requirements to reproduce the statistical analysis can be found at 'covid19_brazil_hfr.yml' in our github directory.</p> <p>Pangolin v.3.0.6, Pangolearn v.1.2.12, scorpio lineage (https://github.com/cov-lineages/pangolin), BEAST v0.10.4 (https://github.com/beast-dev/beast-mcmc/releases/tag/v1.10.4) and v1.10.5 (https://github.com/beast-dev/beast-mcmc/releases/tag/v1.10.5pre_thorney_v0.1.2), MAFFT, version 7 (https://mafft.cbrc.jp/alignment/software/source.html), TempEst v.1.5.3. (http://tree.bio.ed.ac.uk/software/tempest), Tracer v.1.7 (https://github.com/beast-dev/tracer/releases/tag/v1.7) and the ARTIC bioinformatics pipeline (https://github.com/articnetwork/fieldbioinformatics) were used for phylogenetic analyses.</p> <p>Further, we used the TreeMarkovJumpHistoryAnalyzer tool, available at 'inst/utis/P.1_MJumps_complete_history.xml' in our github directory.</p> |

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio [guidelines for submitting code & software](#) for further information.

Data

Policy information about [availability of data](#)

All manuscripts must include a [data availability statement](#). This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our [policy](#)

All source code and data necessary for the replication of our results are available at https://github.com/CADDE-CENTRE/covid19_brazil_hfr (DOI:10.5281/zenodo.6373425).

These datasets were derived from the following public domain resources: the SIVEP-Gripe platform <https://opendatasus.saude.gov.br/dataset/srag-2020>, <https://opendatasus.saude.gov.br/dataset/srag-2021-e2022>; the Brazilian Civil Registry <https://transparencia.registrocivil.org.br/>; the Brazilian Ministry of Health; <https://opendatasus.saude.gov.br/dataset/covid-19-vacinacao>; the National Household Sample Survey COVID-19 <https://www.ibge.gov.br/estatisticas/sociais/populacao/9171-pesquisa-nacional-poramostra-de-domicilios-continua-mensal.html?=&t=o-que-e>; and Brazil's National Register of Health Facilities <https://datasus.saude.gov.br/transferecia-de-arquivos/>

Data from the Brazilian Civil Registry was accessed on the 9th of August through <https://github.com/capyvara/brazil-civil-registry-data>.

The downloaded and processed versions are also available in our Github repository at: [inst/data/SIVEP_hospital_31-01-2022-all.rds](#); [inst/data/registry_covid_detailed_09-08-2021.csv](#); [inst/data/aggregated_vaccinations_210805.rds](#); [inst/data/PNADc_populationpyramids_210617.csv](#); [inst/data/genomic_data_210702.csv](#); [inst/data/IPEA_ICUbeds_physicians_210928.csv](#)

Field-specific reporting

Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.

☒ Life sciences ☐ Behavioural & social sciences ☐ Ecological, evolutionary & environmental sciences

For a reference copy of the document with all sections, see [nature.com/documents/nr-reporting-summary-flat.pdf](https://www.nature.com/documents/nr-reporting-summary-flat.pdf)

Life sciences study design

All studies must disclose on these points even when the disclosure is negative.

Sample size	Sample sizes for our datasets were calculated as the number of Severe Acute Respiratory Infections (SARI) reported to the SIVEP-Gripe platform satisfying different criteria. Sample sizes are reported in the Introduction of the main text and schematized in Figure 1.
Data exclusions	Criteria for inclusion of each reported SARI case in our datasets are discussed in the Introduction of the main text. Briefly, we excluded: - patients confirmed with respiratory pathogens other than SARS-CoV-2, or with unreported cause as our focus was COVID-19 severity; - non-resident patients, to preserve the same population denominators as in the population size estimates; - patients with proof of vaccine administration, to avoid confounding of time trends in fatality rates and vaccine rollout; The above exclusion criteria were pre-established.
Replication	Analyses were performed independently for each city, and thus estimates from each location provide independent support into the inferred relationships between in-hospital fatality rates, healthcare inequities, and healthcare pressure.
Randomization	The findings are derived from a retrospective longitudinal observational study on fatality rates in hospitalised patients and as such randomisation was infeasible.
Blinding	All data sources are publicly and freely available.

Reporting for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

Materials & experimental systems

n/a	Involved in the study
☒	☐ Antibodies
☒	☐ Eukaryotic cell lines
☒	☐ Palaeontology and archaeology
☒	☐ Animals and other organisms
☒	☐ Human research participants
☒	☐ Clinical data
☒	☐ Dual use research of concern

Methods

n/a	Involved in the study
☒	☐ ChIP-seq
☒	☐ Flow cytometry
☒	☐ MRI-based neuroimaging